1
|
Lorenzon R, Ribet C, Pitoiset F, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Cacoub P, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Vicaut E, Rosenzwajg M, Klatzmann D. The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial. J Autoimmun 2024; 144:103172. [PMID: 38330545 DOI: 10.1016/j.jaut.2024.103172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Revised: 01/15/2024] [Accepted: 01/25/2024] [Indexed: 02/10/2024]
Abstract
BACKGROUND A Tregs insufficiency is central to autoimmune and inflammatory diseases pathophysiology and low dose interleukin-2 (IL-2LD) can specifically activate Tregs. OBJECTIVE To assess IL-2LD therapeutic potential and select diseases for further clinical development, we performed an open-label, phase 2a, disease-finding, "basket trial" involving patients with one of 13 different autoimmune diseases. METHODS 81 patients treated with IL-2LD (1 million IU/day) for 5 days, followed by fortnightly injections. The first 48 patients received diluted Proleukin®, while the subsequent 33 received ready-to-use ILT-101®. The primary endpoint was the change in Tregs at day-8 compared to baseline. Key secondary endpoints included clinical efficacy assessments using the Clinical Global Impression (CGI) scale, disease-specific scores, and EuroQL-5D-5L. RESULTS Our study unveiled a universal and significant expansion and activation of Tregs, without concomitant Teffs activation, across all 13 autoimmune diseases. Both Proleukin® and ready-to-use ILT-101® demonstrated identical effects on Tregs. CGI scores reflecting activity, severity, and efficacy were significantly reduced in the overall patient population. Disease-specific clinical scores improved in five of the six disease cohorts with at least six patients, namely ankylosing spondylitis, systemic lupus erythematosus, Behçet's disease, Sjögren's syndrome, and systemic sclerosis. Urticaria was the only severe adverse event related to treatment. CONCLUSION IL-2LD was well-tolerated, exhibiting specific Treg activation and clinical improvements across the 13 autoimmune diseases. CLINICAL IMPLICATION Tregs stimulation by IL-2LD is a promising therapeutic strategy and IL-2LD holds considerable promise for integration into combinatorial therapeutic approaches.
Collapse
Affiliation(s)
- Roberta Lorenzon
- Assistance Publique - Hopitaux de Paris, Biotherapies Department, Pitié-Salpêtrière Hospital, Paris, Île-de-France, France; Sorbonne Universite, INSERM, UMR_S 959, Immunology-Immunopathology- Immunotherapy (i3) Laboratory, Paris, Île-de-France, France
| | - Claire Ribet
- Assistance Publique - Hopitaux de Paris, Biotherapies Department, Pitié-Salpêtrière Hospital, Paris, Île-de-France, France; Sorbonne Universite, INSERM, UMR_S 959, Immunology-Immunopathology- Immunotherapy (i3) Laboratory, Paris, Île-de-France, France
| | - Fabien Pitoiset
- Assistance Publique - Hopitaux de Paris, Biotherapies Department, Pitié-Salpêtrière Hospital, Paris, Île-de-France, France; Sorbonne Universite, INSERM, UMR_S 959, Immunology-Immunopathology- Immunotherapy (i3) Laboratory, Paris, Île-de-France, France
| | - Selim Aractingi
- Assistance Publique - Hopitaux de Paris, Dermatology Department, Cochin Hospital, Paris, Île-de-France, France
| | - Beatrice Banneville
- Assistance Publique - Hopitaux de Paris, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, Île-de-France, France
| | - Laurent Beaugerie
- Assistance Publique - Hopitaux de Paris, Gastroenterology Department, Saint-Antoine Hospital, Paris, Île-de-France, France; Sorbonne Universite, GRC-UPMC 03, Paris, Île-de-France, France
| | - Francis Berenbaum
- Assistance Publique - Hopitaux de Paris, Rheumatology Department, Saint-Antoine Hospital Paris, Île-de-France, France; Sorbonne Universite, INSERM UMR_S938, Paris, Île-de-France, France
| | - Patrice Cacoub
- Assistance Publique - Hopitaux de Paris, Internal Medicine and Clinical Immunology Department, Pitié-Salpêtrière Hospital, Paris, Île-de-France, France
| | - Julien Champey
- Assistance Publique - Hopitaux de Paris, Rheumatology Department, Saint-Antoine Hospital Paris, Île-de-France, France
| | - Olivier Chazouilleres
- Assistance Publique - Hopitaux de Paris, Hepatology Department, Saint-Antoine Hospital, Paris, Île-de-France, France
| | - Christophe Corpechot
- Assistance Publique - Hopitaux de Paris, Hepatology Department, Saint-Antoine Hospital, Paris, Île-de-France, France
| | - Bruno Fautrel
- Assistance Publique - Hopitaux de Paris, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, Île-de-France, France; Sorbonne Universite, GRC08 - IPLESP, Paris, Île-de-France, France
| | - Arsène Mekinian
- Assistance Publique - Hopitaux de Paris, Internal Medicine Department, Saint-Antoine Hospital, Paris, Île-de-France, France
| | - Elodie Regnier
- Assistance Publique - Hopitaux de Paris, Dermatology Department, Cochin Hospital, Paris, Île-de-France, France
| | - David Saadoun
- Assistance Publique - Hopitaux de Paris, Internal Medicine and Clinical Immunology Department, Pitié-Salpêtrière Hospital, Paris, Île-de-France, France
| | - Joe-Elie Salem
- INSERM, CIC-1901, Pitié-Salpêtrière Hospital, Paris, Île-de-France, France; Assistance Publique - Hopitaux de Paris, Pharmacology Department, Pitié-Salpêtrière Hospital, Paris, Île-de-France, France
| | - Jérémie Sellam
- Assistance Publique - Hopitaux de Paris, Rheumatology Department, Saint-Antoine Hospital Paris, Île-de-France, France; Sorbonne Universite, INSERM UMR_S938, Paris, Île-de-France, France
| | - Philippe Seksik
- Assistance Publique - Hopitaux de Paris, Gastroenterology Department, Saint-Antoine Hospital, Paris, Île-de-France, France; Sorbonne Universite, GRC-UPMC 03, Paris, Île-de-France, France
| | - Eric Vicaut
- Assistance Publique - Hopitaux de Paris, Clinical Research Unit, Lariboisiere Fernand-Widal Hospital, Paris, Île-de-France, France
| | - Michelle Rosenzwajg
- Assistance Publique - Hopitaux de Paris, Biotherapies Department, Pitié-Salpêtrière Hospital, Paris, Île-de-France, France; Sorbonne Universite, INSERM, UMR_S 959, Immunology-Immunopathology- Immunotherapy (i3) Laboratory, Paris, Île-de-France, France
| | - David Klatzmann
- Assistance Publique - Hopitaux de Paris, Biotherapies Department, Pitié-Salpêtrière Hospital, Paris, Île-de-France, France; Sorbonne Universite, INSERM, UMR_S 959, Immunology-Immunopathology- Immunotherapy (i3) Laboratory, Paris, Île-de-France, France.
| |
Collapse
|
2
|
Puszkiel A, Bianconi G, Pasquiers B, Balakirouchenane D, Arrondeau J, Boudou-Rouquette P, Bretagne MC, Salem JE, Declèves X, Vidal M, Kramkimel N, Guegan S, Aractingi S, Huillard O, Alexandre J, Wislez M, Goldwasser F, Blanchet B. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients. Br J Cancer 2024:10.1038/s41416-024-02659-x. [PMID: 38532102 DOI: 10.1038/s41416-024-02659-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 03/05/2024] [Accepted: 03/12/2024] [Indexed: 03/28/2024] Open
Abstract
BACKGROUND Reducing nivolumab dose intensity could increase patients' life quality and decrease the financial burden while maintaining efficacy. The aims of this study were to develop a population PK model of nivolumab based on data from unselected metastatic cancer patients and to simulate extended-interval regimens allowing to maintain minimal effective plasma concentrations (MEPC). METHODS Concentration-time data (992 plasma nivolumab concentrations, 364 patients) were modeled using a two-compartment model with linear elimination clearance in Monolix software. Extended-interval regimens allowing to maintain steady-state trough concentrations (Cmin,ss) above the MEPC of 2.5 mg/L or 1.5 mg/L in >90% of patients were simulated. RESULTS Increasing 3-times the dosing interval from 240 mg every two weeks (Q2W) to Q6W and 2-times from 480 mg Q4W to Q8W resulted in Cmin,ss above 2.5 mg/L in 95.8% and 95.4% of patients, respectively. 240 mg Q8W and 480 mg Q10W resulted in Cmin,ss above 1.5 mg/L in 91.0% and 91.8% of patients, respectively. Selection of a 240 mg Q6W regimen would decrease by 3-fold the annual treatment costs compared to standard regimen of 240 mg Q2W (from 78,744€ to 26,248€ in France). CONCLUSIONS Clinical trials are warranted to confirm the non-inferiority of extended-interval compared to standard regimen.
Collapse
Affiliation(s)
- Alicja Puszkiel
- Université Paris Cité, Faculté de Pharmacie de Paris, INSERM UMR-S1144, Paris, France.
- Biologie du Médicament - Toxicologie, Cochin University Hospital, AP-HP, Paris, France.
| | - Guillaume Bianconi
- Biologie du Médicament - Toxicologie, Cochin University Hospital, AP-HP, Paris, France
| | - Blaise Pasquiers
- Université Paris Cité, Faculté de Pharmacie de Paris, INSERM UMR-S1144, Paris, France
- PhinC Development, Massy, France
| | | | - Jennifer Arrondeau
- Department of Medical Oncology, Cochin University Hospital, Institut du Cancer Paris CARPEM, AP-HP, Paris, France
| | - Pascaline Boudou-Rouquette
- Department of Medical Oncology, Cochin University Hospital, Institut du Cancer Paris CARPEM, AP-HP, Paris, France
| | - Marie-Claire Bretagne
- Department of Pharmacology, Pharmacovigilance Unit, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
| | - Joe-Elie Salem
- Department of Pharmacology, Pharmacovigilance Unit, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
- INSERM, CIC-1901, Sorbonne Université, Paris, France
| | - Xavier Declèves
- Université Paris Cité, Faculté de Pharmacie de Paris, INSERM UMR-S1144, Paris, France
- Biologie du Médicament - Toxicologie, Cochin University Hospital, AP-HP, Paris, France
| | - Michel Vidal
- Biologie du Médicament - Toxicologie, Cochin University Hospital, AP-HP, Paris, France
- Université Paris Cité, Faculté de Pharmacie de Paris, UMR8038 CNRS CiTCoM, U1268 INSERM, CARPEM, Paris, France
| | - Nora Kramkimel
- Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
| | - Sarah Guegan
- Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
| | - Selim Aractingi
- Department of Dermatology, Cochin University Hospital, AP-HP, Paris, France
| | - Olivier Huillard
- Department of Medical Oncology, Cochin University Hospital, Institut du Cancer Paris CARPEM, AP-HP, Paris, France
| | - Jérôme Alexandre
- Department of Medical Oncology, Cochin University Hospital, Institut du Cancer Paris CARPEM, AP-HP, Paris, France
- Université Paris Cité, INSERM, Centre de Recherche des Cordeliers, Équipe labélisée Ligue Contre le Cancer, CNRS SNC 5096, Sorbonne Université, Paris, France
| | - Marie Wislez
- Department of Pneumology, Cochin University Hospital, AP-HP, Paris, France
| | - François Goldwasser
- Department of Medical Oncology, Cochin University Hospital, Institut du Cancer Paris CARPEM, AP-HP, Paris, France
- Université Paris Cité, Faculté de Médecine, INSERM, U1016, Institut Cochin, Paris, France
| | - Benoit Blanchet
- Biologie du Médicament - Toxicologie, Cochin University Hospital, AP-HP, Paris, France
- Université Paris Cité, Faculté de Pharmacie de Paris, UMR8038 CNRS CiTCoM, U1268 INSERM, CARPEM, Paris, France
| |
Collapse
|
3
|
Kosmider O, Possémé C, Templé M, Corneau A, Carbone F, Duroyon E, Breillat P, Chirayath TW, Oules B, Sohier P, Luka M, Gobeaux C, Lazaro E, Outh R, Le Guenno G, Lifermann F, Berleur M, Le Mene M, Friedrich C, Lenormand C, Weitten T, Guillotin V, Burroni B, Boussier J, Willems L, Aractingi S, Dionet L, Tharaux PL, Vergier B, Raynaud P, Ea HK, Ménager M, Duffy D, Terrier B. VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. Nat Commun 2024; 15:910. [PMID: 38291039 PMCID: PMC10828464 DOI: 10.1038/s41467-024-44811-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2022] [Accepted: 01/02/2024] [Indexed: 02/01/2024] Open
Abstract
Acquired mutations in the UBA1 gene were recently identified in patients with severe adult-onset auto-inflammatory syndrome called VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic). However, the precise physiological and clinical impact of these mutations remains poorly defined. Here we study a unique prospective cohort of VEXAS patients. We show that monocytes from VEXAS are quantitatively and qualitatively impaired and display features of exhaustion with aberrant expression of chemokine receptors. In peripheral blood from VEXAS patients, we identify an increase in circulating levels of many proinflammatory cytokines, including IL-1β and IL-18 which reflect inflammasome activation and markers of myeloid cells dysregulation. Gene expression analysis of whole blood confirms these findings and also reveals a significant enrichment of TNF-α and NFκB signaling pathways that can mediate cell death and inflammation. This study suggests that the control of the nflammasome activation and inflammatory cell death could be therapeutic targets in VEXAS syndrome.
Collapse
Affiliation(s)
- Olivier Kosmider
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France.
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France.
| | - Céline Possémé
- Institut Pasteur, Université de Paris Cité, Translational Immunology Unit, Paris, France
| | - Marie Templé
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Aurélien Corneau
- Sorbonne Université, Faculté de Médecine, UMS037, PASS, Plateforme de Cytométrie de la Pitié-Salpêtrière CyPS, Paris, France
| | - Francesco Carbone
- Université de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, Paris, France
- Labtech Single-Cell@Imagine, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Eugénie Duroyon
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Paul Breillat
- Université de Paris Cité, INSERM, U970, PARCC, F-, Paris, France
- Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France
| | | | - Bénédicte Oules
- Department of Pathology, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France
| | - Pierre Sohier
- Department of Pathology, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France
| | - Marine Luka
- Université de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, Paris, France
- Labtech Single-Cell@Imagine, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Camille Gobeaux
- Biochemistry Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Estibaliz Lazaro
- Department of Internal Medicine, Bordeaux University Hospital-Haut-Lévêque, Pessac, France
| | - Roderau Outh
- Department of Internal Medicine, Centre Hospitalier de Perpignan, Perpignan, France
| | - Guillaume Le Guenno
- Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | | | - Marie Berleur
- Department of Internal Medicine, AP-HP, APHP-NUP, Hôpital Bichat, Paris, France
| | - Melchior Le Mene
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Chloé Friedrich
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Cédric Lenormand
- Université de Strasbourg, Department of Dermatology, CHRU Strasbourg, Strasbourg, France
| | - Thierry Weitten
- Department of Internal Medicine, Centre Hospitalier (CHICAS), Gap, France
| | - Vivien Guillotin
- Department of Internal Medicine, Bordeaux University Hospital-Saint-André, Bordeaux, France
| | - Barbara Burroni
- Department of Pathology, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France
| | - Jeremy Boussier
- Sorbonne University - 47-83 Boulevard de l'Hopital, Paris, France
| | - Lise Willems
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
- Hematology Department, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Selim Aractingi
- Dermatology Department, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Léa Dionet
- Université de Paris Cité, INSERM, U970, PARCC, F-, Paris, France
| | | | - Béatrice Vergier
- Pathology Department, Bordeaux University Hospital-Haut-Lévêque, Pessac, France
| | - Pierre Raynaud
- Pathology Department, Centre Hospitalier de Perpignan, Perpignan, France
| | - Hang-Korng Ea
- Université de Paris Cité, INSERM, UMR-S 1132 BIOSCAR, Paris, France
- Rheumatology Department, AP- HP, Lariboisière Hospital, Paris, France
| | - Mickael Ménager
- Université de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, Paris, France
- Labtech Single-Cell@Imagine, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Darragh Duffy
- Institut Pasteur, Université de Paris Cité, Translational Immunology Unit, Paris, France
| | - Benjamin Terrier
- Université de Paris Cité, INSERM, U970, PARCC, F-, Paris, France.
- Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France.
| |
Collapse
|
4
|
Cohen E, Lheure C, Ingen-Housz-Oro S, Hotz C, Bettuzzi T, Chasset F, Descamps V, Deschamps L, Mahevas M, Terrier B, Sohier P, Guegan S, Kramkimel N, Darbord D, Chanal J, Oulès B, Aractingi S, Seta V, Dupin N. Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients. Eur J Dermatol 2023; 33:680-685. [PMID: 38465550 DOI: 10.1684/ejd.2023.4584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
Sarcoidosis is a systemic disease that affects the skin in about 25% of patients. The treatment of cutaneous sarcoidosis is guided by the extent of lesions, associated symptoms and organ involvement. To evaluate rates of response to various potential first-line treatments for cutaneous sarcoidosis during the year following treatment initiation. This retrospective multicentre study included 120 patients with cutaneous sarcoidosis. Treatment response was assessed retrospectively from the patients' medical records. Univariate logistic regression analysis, with an estimation of unadjusted odds ratios (OR) and their 95% CI ,was performed to identify factors associated with complete cutaneous remission (CR), followed by multivariate logistic regression analysis. At one year, 43 of the 120 (36%) included patients had CR. The best response rates were obtained with oral corticosteroids (12/21, 57%), followed by a combination of hydroxychloroquine and topical steroids (6/13, 46%). In multivariate analysis, lupus pernio was the only predictor of a poor cutaneous response. We suggest the use of a combination of hydroxychloroquine and topical steroids as an optimal first-line treatment for cutaneous sarcoidosis, given the known adverse effects of systemic corticosteroids.
Collapse
Affiliation(s)
- Elisabeth Cohen
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Coralie Lheure
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, APHP, Mondor Hospital, Paris, France, EpiDermE, University Paris Est Créteil, Créteil, France
| | - Claire Hotz
- Department of Dermatology, APHP, Mondor Hospital, Paris, France
| | - Thomas Bettuzzi
- Department of Dermatology, APHP, Mondor Hospital, Paris, France
| | | | | | - Lydia Deschamps
- Department of Pathology, APHP, Bichat Hospital, Paris, France
| | - Matthieu Mahevas
- Department of Internal Medicine, APHP, Mondor Hospital, Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine, APHP, Cochin Hospital, Paris, France
| | - Pierre Sohier
- Department of Pathology, APHP, Cochin Hospital, Paris, France
| | - Sarah Guegan
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Nora Kramkimel
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | | | - Johan Chanal
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Benedicte Oulès
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Selim Aractingi
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Vannina Seta
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| | - Nicolas Dupin
- Department of Dermatology, APHP, Cochin Hospital, Paris, France
| |
Collapse
|
5
|
Parlati L, Sakka M, Retbi A, Bouam S, Hassani L, Meritet JF, Rufat P, Bonnefont-Rousselot D, Batista R, Terris B, Bellanger A, Thabut D, Vozy A, Spano JP, Coriat R, Goldwasser F, Aractingi S, Sogni P, Pol S, Mallet V. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors. JHEP Rep 2023; 5:100880. [PMID: 38074948 PMCID: PMC10701119 DOI: 10.1016/j.jhepr.2023.100880] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Revised: 07/10/2023] [Accepted: 07/24/2023] [Indexed: 04/01/2024] Open
Abstract
BACKGROUND & AIMS There is concern about the burden of liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs). METHODS In a retrospective cohort study, we evaluated the likelihood of grade 3/4 liver injury, of grade 3/4 cholestatic liver injury, and of liver failure, as per the Common Terminology Criteria for Adverse Events (CTCAE) version 5, following treatment with ICIs. We compared these occurrences with a group of cancer patients who were propensity-matched and treated with conventional chemotherapy. For all ICI patients experiencing grade 3/4 liver injury, we conducted a causality assessment using the RUCAM method and examined patient outcomes. RESULTS Among 952 patients (median [IQR] age 66 [57-73] years, 64% males) who were treated with ICI between January 1, 2015, and December 31, 2019, a total of 86 (9%) progressed to grade 3/4 liver injury, and liver failure was not observed. Anti-PD-(L)1/anti-CTLA-4 antibodies combinations (adjusted hazard ratio 3.36 [95% CI: 1.67-6.79]; p <0.001), and chronic hepatitis B (adjusted hazard ratio 5.48 [95% CI: 1.62-18.5]; p = 0.006], were independent risk factors. Liver injury was attributed to ICI treatment in 19 (2.0%) patients. Patients with ICI toxicity typically presented with granulomatous hepatitis or cholangiocyte inflammation. ICI withdrawal was associated with cancer progression and mortality. Re-introduction of ICI was not associated with recurrent grade 3/4 liver injury. Compared with matched patients treated with conventional, non-ICI-based chemotherapy, anti-PD-(L)1/anti-CTLA-4 combinations (p <0.001) and anti-PD-(L)1 monotherapies (p = 0.053) increased the risk of grade 3/4 liver injury and of grade 3/4 cholestatic liver injury, respectively. CONCLUSIONS An increased risk of grade 3/4 liver injury under anti-PD-(L)1/anti-CTLA-4 antibodies was observed, whereas no substantial increase in the likelihood of liver failure occurred even after treatment reintroduction. IMPACT AND IMPLICATIONS There is concern about liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs). We investigated the burden of grade 3/4 liver injury after treatment with ICIs in a multicentric cohort of patients with cancer. Overall, a 9% incidence of grade 3/4 liver injury was detected after ICIs, and direct ICI hepatotoxicity was demonstrated in 2% of patients. Anti-PD-(L)1/Anti-CTLA-4 antibody combinations, and chronic HBV infection were independent risk factors. ICI withdrawal for grade 3/4 liver injury was associated with cancer progression. Re-introduction of ICI treatment was not associated with recurrent grade 3/4 liver injury.
Collapse
Affiliation(s)
- Lucia Parlati
- Université Paris Cité, Paris, France
- Service de Maladies du foie, AP-HP.Centre, DMU Cancérologie et Spécialités Médico-Chirurgicales, Groupe Hospitalier Cochin Port Royal, Paris, France
| | - Mehdi Sakka
- Service de Biochimie Métabolique, AP-HP.Sorbonne Université, Hôpitaux Universitaires Pitié Salpêtrière–Charles Foix, Paris, France
| | - Aurelia Retbi
- Département d’Information Médicale, AP-HP.Sorbonne Université, DMU Esprit, Hôpitaux Universitaires Pitié Salpêtrière–Charles Foix, Paris, France
| | - Samir Bouam
- Unité d’Information Médicale, AP-HP.Centre, DMU Prime, Groupe Hospitalier Cochin Port Royal, Paris, France
| | - Lamia Hassani
- Pharmacie à Usage Intérieur, AP-HP.Sorbonne Université, Hôpitaux Universitaires Pitié Salpêtrière–Charles Foix, Paris, France
| | - Jean-François Meritet
- Service de Virologie, AP-HP.Centre, DMU Biophygen, Groupe Hospitalier Cochin Port Royal, Paris, France
| | - Pierre Rufat
- Département d’Information Médicale, AP-HP.Sorbonne Université, DMU Esprit, Hôpitaux Universitaires Pitié Salpêtrière–Charles Foix, Paris, France
| | - Dominique Bonnefont-Rousselot
- Université Paris Cité, Paris, France
- Service de Biochimie Métabolique, AP-HP.Sorbonne Université, Hôpitaux Universitaires Pitié Salpêtrière–Charles Foix, Paris, France
- CNRS, INSERM, UTCBS, Paris, France
| | - Rui Batista
- Pharmacie Clinique, AP-HP.Centre, DMU Prime, Groupe Hospitalier Cochin Port Royal, Paris, France
| | - Benoit Terris
- Université Paris Cité, Paris, France
- Service d’Anatomopathologie, AP-HP.Centre, DMU Prime, Groupe Hospitalier Cochin Port Royal, Paris, France
| | - Agnès Bellanger
- Département d’Information Médicale, AP-HP.Sorbonne Université, DMU Esprit, Hôpitaux Universitaires Pitié Salpêtrière–Charles Foix, Paris, France
| | - Dominique Thabut
- Université Paris-Sorbonne, Paris, France
- Service d’Hépatogastroentérologie, AP-HP.Sorbonne Université, DMU Sapere, Hôpitaux Universitaires Pitié Salpêtrière–Charles Foix, Paris, France
| | - Aurore Vozy
- Université Paris-Sorbonne, Paris, France
- Service d’Oncologie Médicale, AP-HP.Sorbonne Université, DMU Orphe, Hôpitaux Universitaires Pitié Salpêtrière–Charles Foix, Paris, France
| | - Jean-Philippe Spano
- Université Paris-Sorbonne, Paris, France
- Service d’Oncologie Médicale, AP-HP.Sorbonne Université, DMU Orphe, Hôpitaux Universitaires Pitié Salpêtrière–Charles Foix, Paris, France
| | - Romain Coriat
- Université Paris Cité, Paris, France
- Service de Gastroentérologie et Oncologie Digestive, AP-HP.Centre, DMU Cancérologie et Spécialités Médico-Chirurgicales, Groupe Hospitalier Cochin Port Royal, Paris, France
| | - François Goldwasser
- Université Paris Cité, Paris, France
- Service de Cancérologie, AP-HP.Centre, DMU Cancérologie et Spécialités Médico-Chirurgicales, Groupe Hospitalier Cochin Port Royal, Paris, France
| | - Selim Aractingi
- Université Paris Cité, Paris, France
- Département de Dermatologie, AP-HP.Centre, DMU Endromed, Groupe Hospitalier Cochin Port Royal, Paris, France
| | - Philippe Sogni
- Université Paris Cité, Paris, France
- Service de Maladies du foie, AP-HP.Centre, DMU Cancérologie et Spécialités Médico-Chirurgicales, Groupe Hospitalier Cochin Port Royal, Paris, France
| | - Stanislas Pol
- Université Paris Cité, Paris, France
- Service de Maladies du foie, AP-HP.Centre, DMU Cancérologie et Spécialités Médico-Chirurgicales, Groupe Hospitalier Cochin Port Royal, Paris, France
| | - Vincent Mallet
- Université Paris Cité, Paris, France
- Service de Maladies du foie, AP-HP.Centre, DMU Cancérologie et Spécialités Médico-Chirurgicales, Groupe Hospitalier Cochin Port Royal, Paris, France
| |
Collapse
|
6
|
Dangien A, Darbord D, Chanal J, Wendling J, Pantoja C, Oules B, Lheure C, Ouedraogo E, Kramkimel N, Barret M, Beuvon F, Plantier F, Guegan S, Aractingi S, Seta V, Sohier P, Isnard C, Dupin N. SARS-CoV-2 vaccination may trigger and exacerbate mucosal lichen planus. J Eur Acad Dermatol Venereol 2023; 37:e1094-e1096. [PMID: 37114298 DOI: 10.1111/jdv.19144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 04/17/2023] [Indexed: 04/29/2023]
Affiliation(s)
- A Dangien
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
| | - D Darbord
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
| | - J Chanal
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
- Institut Cochin, INSERM U1016, UMR 8104, Paris, France
| | - J Wendling
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
| | - C Pantoja
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
| | - B Oules
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
- Institut Cochin, INSERM U1016, UMR 8104, Paris, France
- Faculté de Médecine Paris Centre Santé, Université Paris Cité, Paris, France
| | - C Lheure
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
| | - E Ouedraogo
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
| | - N Kramkimel
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
| | - M Barret
- Gastroenterology Department, Hôpital Cochin, AP-HP, Paris, France
| | - F Beuvon
- Pathology Department, Hôpital Cochin, AP-HP, Paris, France
| | - F Plantier
- Pathology Department, Hôpital Cochin, AP-HP, Paris, France
| | - S Guegan
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
- Institut Cochin, INSERM U1016, UMR 8104, Paris, France
- Faculté de Médecine Paris Centre Santé, Université Paris Cité, Paris, France
| | - S Aractingi
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
- Institut Cochin, INSERM U1016, UMR 8104, Paris, France
- Faculté de Médecine Paris Centre Santé, Université Paris Cité, Paris, France
| | - V Seta
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
| | - P Sohier
- Institut Cochin, INSERM U1016, UMR 8104, Paris, France
- Faculté de Médecine Paris Centre Santé, Université Paris Cité, Paris, France
- Pathology Department, Hôpital Cochin, AP-HP, Paris, France
| | - C Isnard
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
| | - N Dupin
- Dermatology Department, Hôpital Cochin, AP-HP, Paris, France
- Institut Cochin, INSERM U1016, UMR 8104, Paris, France
- Faculté de Médecine Paris Centre Santé, Université Paris Cité, Paris, France
| |
Collapse
|
7
|
Al-Hage J, Masliah-Planchon J, Sohier P, Lumbroso-Rouic L, Bieche I, Aractingi S. Unusually Aggressive Actinic Keratosis of the Eyelid and Conjunctiva. Acta Derm Venereol 2023; 103:adv4500. [PMID: 37605896 PMCID: PMC10461307 DOI: 10.2340/actadv.v103.4500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Accepted: 02/28/2023] [Indexed: 08/23/2023] Open
Abstract
Abstract is missing (Short communication)
Collapse
Affiliation(s)
- Jana Al-Hage
- Department of Dermatology, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre Cochin Hôtel Dieu-Broca, 89 rue d'Assas, 75006 Paris, France
| | - Julien Masliah-Planchon
- Department of Biopathology, Institut Curie, PSL Research University, Paris, France; Department of Genetics, Institut Curie, Paris, France
| | - Pierre Sohier
- University of Paris, Faculté de Médecine Paris Centre, 12 rue de l'École de médecine 75006 Paris, France; Department of Pathology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, AP-HP Centre-Université de Paris, 27 rue du Faubourg St Jacques, 75014 Paris, France
| | | | - Ivan Bieche
- Department of Genetics, Institut Curie, Paris, France; Faculty of Pharmaceutical and Biological Sciences, INSERM U1016 Research Unit, Paris Descartes University, Paris, France
| | - Selim Aractingi
- Department of Dermatology, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre Cochin Hôtel Dieu-Broca, 89 rue d'Assas, 75006 Paris, France; University of Paris, Faculté de Médecine Paris Centre, 12 rue de l'École de médecine 75006 Paris, France; Cutaneous Biology Lab, Institut Cochin, INSERM U1016, UMR8104, 24 rue du Faubourg St Jacques, 75014 Paris, France.
| |
Collapse
|
8
|
du Halgouet A, Darbois A, Alkobtawi M, Mestdagh M, Alphonse A, Premel V, Yvorra T, Colombeau L, Rodriguez R, Zaiss D, El Morr Y, Bugaut H, Legoux F, Perrin L, Aractingi S, Golub R, Lantz O, Salou M. Role of MR1-driven signals and amphiregulin on the recruitment and repair function of MAIT cells during skin wound healing. Immunity 2023; 56:78-92.e6. [PMID: 36630919 PMCID: PMC9839364 DOI: 10.1016/j.immuni.2022.12.004] [Citation(s) in RCA: 22] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2022] [Revised: 09/02/2022] [Accepted: 12/06/2022] [Indexed: 01/11/2023]
Abstract
Tissue repair processes maintain proper organ function following mechanical or infection-related damage. In addition to antibacterial properties, mucosal associated invariant T (MAIT) cells express a tissue repair transcriptomic program and promote skin wound healing when expanded. Herein, we use a human-like mouse model of full-thickness skin excision to assess the underlying mechanisms of MAIT cell tissue repair function. Single-cell RNA sequencing analysis suggested that skin MAIT cells already express a repair program at steady state. Following skin excision, MAIT cells promoted keratinocyte proliferation, thereby accelerating healing. Using skin grafts, parabiosis, and adoptive transfer experiments, we show that MAIT cells migrated into the wound in a T cell receptor (TCR)-independent but CXCR6 chemokine receptor-dependent manner. Amphiregulin secreted by MAIT cells following excision promoted wound healing. Expression of the repair function was probably independent of sustained TCR stimulation. Overall, our study provides mechanistic insights into MAIT cell wound healing function in the skin.
Collapse
Affiliation(s)
| | - Aurélie Darbois
- INSERM U932, PSL University, Institut Curie, 75005 Paris, France
| | - Mansour Alkobtawi
- Cutaneous Biology, Institut Cochin, Inserm 1016, and Université de Paris Cité, 75014 Paris, France
| | - Martin Mestdagh
- INSERM U932, PSL University, Institut Curie, 75005 Paris, France
| | - Aurélia Alphonse
- INSERM U932, PSL University, Institut Curie, 75005 Paris, France
| | - Virginie Premel
- INSERM U932, PSL University, Institut Curie, 75005 Paris, France
| | - Thomas Yvorra
- CNRS UMR 3666, INSERM U1143, Chemical Biology of Cancer Laboratory, PSL University, Institut Curie, 75005 Paris, France
| | - Ludovic Colombeau
- CNRS UMR 3666, INSERM U1143, Chemical Biology of Cancer Laboratory, PSL University, Institut Curie, 75005 Paris, France
| | - Raphaël Rodriguez
- CNRS UMR 3666, INSERM U1143, Chemical Biology of Cancer Laboratory, PSL University, Institut Curie, 75005 Paris, France
| | - Dietmar Zaiss
- Department of Immune Medicine, University of Regensburg, Regensburg, Germany,Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany,Institute of Pathology, University Regensburg, Regensburg, Germany,Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany
| | - Yara El Morr
- INSERM U932, PSL University, Institut Curie, 75005 Paris, France
| | - Hélène Bugaut
- INSERM U932, PSL University, Institut Curie, 75005 Paris, France
| | - François Legoux
- INSERM U932, PSL University, Institut Curie, 75005 Paris, France
| | - Laetitia Perrin
- INSERM U932, PSL University, Institut Curie, 75005 Paris, France
| | - Selim Aractingi
- Cutaneous Biology, Institut Cochin, Inserm 1016, and Université de Paris Cité, 75014 Paris, France
| | - Rachel Golub
- Institut Pasteur, Université Paris Cité, INSERM U1223, 75015 Paris, France
| | - Olivier Lantz
- INSERM U932, PSL University, Institut Curie, 75005 Paris, France; Laboratoire d'Immunologie Clinique, Institut Curie, 75005 Paris, France; Centre d'investigation Clinique en Biothérapie Gustave-Roussy Institut Curie (CIC-BT1428), Institut Curie, 75005 Paris, France.
| | - Marion Salou
- INSERM U932, PSL University, Institut Curie, 75005 Paris, France.
| |
Collapse
|
9
|
Malouf GG, Lu X, Mouawad R, Spano JP, Grange P, Yan F, Aractingi S, Su X, Dupin N. Genetic landscape of indolent and aggressive Kaposi sarcomas. J Eur Acad Dermatol Venereol 2022; 36:2343-2351. [PMID: 35881110 DOI: 10.1111/jdv.18463] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2022] [Accepted: 06/23/2022] [Indexed: 01/12/2023]
Abstract
BACKGROUND Kaposi sarcoma (KS) is a rare skin tumour caused by herpesvirus 8 infection and characterized by either indolence or an aggressive course necessitating systemic therapies. The genetic basis of this difference remains unknown. OBJECTIVES To explore the tumour mutational burden in indolent and aggressive KS. METHODS We performed whole-exome sequencing on a cohort of 21 KS patients. We compared genetic landscape including tumor mutational burden between the two forms of indolent and agressive KS. RESULTS Aggressive KS tumours had a significantly higher TMB and a larger cumulative number of deleterious mutations than indolent KS tumours. In addition, all aggressive tumours had at least three deleterious mutations, whereas most indolent tumours harboured only one or no predicted deleterious mutations. Deleterious mutations listed in the Cancer Gene Census were detected exclusively in patients with aggressive disease. An analysis of somatic copy-number alterations (SCNA) revealed a tendency towards higher number of alterations in aggressive KS. CONCLUSIONS These data suggest that SCNA alterations and an increase in mutational burden promote aggressive KS and that it might be more appropriate to consider indolent KS as an opportunistic skin disease rather than a cancer.
Collapse
Affiliation(s)
- G G Malouf
- Department of Medical Oncology, Institut de Cancérologie de Strasbourg, Strasbourg University, Strasbourg, France.,Department of Cancer and Functional Genomics, Institute of Genetics and Molecular and Cellular Biology, CNRS/INSERM/UNISTRA, Illkirch, France
| | - X Lu
- Department of Cancer and Functional Genomics, Institute of Genetics and Molecular and Cellular Biology, CNRS/INSERM/UNISTRA, Illkirch, France.,State Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China
| | - R Mouawad
- Department of Medical Oncology, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne University, Paris, France
| | - J-P Spano
- Department of Medical Oncology, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne University, Paris, France
| | - P Grange
- Department of Dermatology, Cochin Hospital, Assistance Publique des Hôpitaux de Paris, Paris Cité University, Paris, France.,Institut Cochin, Inserm 1016, Paris, France
| | - F Yan
- State Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China
| | - S Aractingi
- Department of Dermatology, Cochin Hospital, Assistance Publique des Hôpitaux de Paris, Paris Cité University, Paris, France.,Institut Cochin, Inserm 1016, Paris, France
| | - X Su
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - N Dupin
- Department of Dermatology, Cochin Hospital, Assistance Publique des Hôpitaux de Paris, Paris Cité University, Paris, France.,Institut Cochin, Inserm 1016, Paris, France
| |
Collapse
|
10
|
Guerrois F, Hassan E, Bettuzzi T, Seta V, Goulvestre C, Jelti L, Belmondo T, Wolkenstein P, Aractingi S, Ingen-Housz-Oro S, Dupin N. Bullous pemphigoid: Three main clusters defining 3 outcome profiles. J Am Acad Dermatol 2022; 87:359-365. [PMID: 35483492 DOI: 10.1016/j.jaad.2022.04.029] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 02/27/2022] [Accepted: 04/08/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND Bullous pemphigoid (BP) is the most common autoimmune blistering disorder. Its presentation is polymorphic. OBJECTIVE To investigate different clinical and biological profiles of BP. METHODS We conducted a retrospective 2-center study including all BP patients seen between January 1, 2015, and February 28, 2021. We performed hierarchical clustering on principal components. RESULTS Three clusters were identified. Patients in cluster 1 (n = 155) were older than those in clusters 2 (n = 89) and 3 (n = 35; P < .0001), more frequently presented pauci-bullous BP (n = 63 [41%] vs 14 [16%] and 2 [6%], respectively; P < .0001) and had anti-BP230 antibodies in 87% of cases. More than 100 blisters were observed in 14 patients (40%) from cluster 3, versus 3 (2%) from cluster 1 and 0 (0%) from cluster 2 (P < .0001). Frequency of mucosal involvement was higher in cluster 3 (n = 32 [91%, including epiglottis in 40%] vs 11 [7%] and 34 [38%]; P < .0001). In clusters 2 and 3, 70% and 74% of patients had antibodies targeting only BP180. Those in cluster 3 received more lines of systemic treatment and experienced more relapses. LIMITATIONS Retrospective study without immunoelectron microscopy. CONCLUSION We identified 3 different BP clusters, including one corresponding to severe BP180+ BP230- BP with features common to mucous membrane pemphigoid.
Collapse
Affiliation(s)
| | - Elsa Hassan
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Thomas Bettuzzi
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France; EpiDermE (Épidémiologie en Dermatologie et Évaluation des Thérapeutiques), Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France
| | - Vannina Seta
- Dermatology Department, AP-HP, Cochin Hospital, Paris, France; Cenpetence Center for Autoimmune Blistering Diseases MALIBUL, AP-HP, Cochin Hospital, Paris, France
| | - Claire Goulvestre
- Immunology and Biology Department, AP-HP, Cochin Hospital, Paris, France
| | - Lamia Jelti
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France; Competence Center for Autoimmune Blistering Diseases, MALIBUL, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Thibaut Belmondo
- Competence Center for Autoimmune Blistering Diseases, MALIBUL, AP-HP, Henri Mondor Hospital, Créteil, France; Immunology and Biology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | | | - Selim Aractingi
- Dermatology Department, AP-HP, Cochin Hospital, Paris, France; Laboratoire de Biologie Cutanée, Institut Cochin, Inserm U1016, Université de Paris, France
| | - Saskia Ingen-Housz-Oro
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France; EpiDermE (Épidémiologie en Dermatologie et Évaluation des Thérapeutiques), Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France; Competence Center for Autoimmune Blistering Diseases, MALIBUL, AP-HP, Henri Mondor Hospital, Créteil, France.
| | - Nicolas Dupin
- Dermatology Department, AP-HP, Cochin Hospital, Paris, France; Competence Center for Autoimmune Blistering Diseases, MALIBUL, AP-HP, Henri Mondor Hospital, Créteil, France; Laboratoire de Biologie Cutanée, Institut Cochin, Inserm U1016, Université de Paris, France
| |
Collapse
|
11
|
Calmettes V, Badrignans M, Konstantinou MP, Tancrède-Bohin E, Vignon-Pennamen MD, Castel M, Pham-Ledard A, Le Roux-Villet C, Misery L, Schoenlaub P, Tronquoy AF, Cordel N, Ortonne N, Sohier P, Cellier L, Tournier E, De La Salle EM, Le Flahec G, Plantier F, Grootenboer-Mignot S, Jouen F, Hillion B, Aractingi S, Duvert-Lehembre S, Dupin N, Ingen-Housz-Oro S. IgA and IgG/IgA intercellular dermatosis: a clinicopathological case series of 15 patients. J Eur Acad Dermatol Venereol 2022; 36:e896-e898. [PMID: 35694900 DOI: 10.1111/jdv.18325] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Accepted: 06/03/2022] [Indexed: 12/16/2022]
Affiliation(s)
- V Calmettes
- Department of Dermatology, Henri Mondor University Hospital, AP-HP, Créteil, France
| | - M Badrignans
- Department of Pathology, Henri Mondor University Hospital, AP-HP, Créteil, France
| | - M P Konstantinou
- Department of Dermatology, University Hospital of Toulouse, Toulouse, France
| | - E Tancrède-Bohin
- Department of Dermatology, Saint Louis University Hospital, APHP, Paris, France
| | - M D Vignon-Pennamen
- Department of Pathology, Saint Louis University Hospital, APHP, Paris, France
| | - M Castel
- Department of Dermatology, University Hospital of Rouen, Rouen, France
| | - A Pham-Ledard
- Department of Dermatology, CHU Bordeaux and INSERM U1312, Bordeaux, France
| | - C Le Roux-Villet
- Department of Dermatology, University Hospital Avicenne, Bobigny, France
| | - L Misery
- Department of Dermatology, University Hospital of Brest, Brest, France
| | - P Schoenlaub
- Department of Dermatology, Hopital d'Instruction des Armées, Brest, France
| | - A F Tronquoy
- Department of Dermatology, Hospital of Boulogne-sur-Mer, Boulogne-sur-Mer, France
| | - N Cordel
- Department of Dermatology and Clinical Immunology, Guadeloupe University Hospital, Pointe-à-Pitre, France
| | - N Ortonne
- Department of Pathology, Henri Mondor University Hospital, AP-HP, Créteil, France
| | - P Sohier
- Department of Pathology, Cochin Hospital, AP-HP, AP-HP, Centre-Université de Paris, Paris, France
| | - L Cellier
- Department of Pathology, University Hospital of Rouen, Rouen, France
| | - E Tournier
- Derpartment of Pathology, University Hospital of Toulouse, Toulouse, France
| | - E M De La Salle
- Department of Pathology, University Hospital of Lille, Lille, France
| | - G Le Flahec
- Department of Pathology, University Hospital of Brest, Brest, France
| | - F Plantier
- Cabinet de Pathologie Mathurin Moreau, Paris, France
| | | | - F Jouen
- Department of Immunology, University Hospital of Rouen, Rouen, France
| | - B Hillion
- Department of Dermatology, Hospital of Marne la Vallée, Jossigny, France
| | - S Aractingi
- Department of Dermatology, Cochin Hospital, AP-HP, AP-HP, Centre-Université de Paris, Paris, France
| | - S Duvert-Lehembre
- Department of Dermatology, Hospital of Dunkerque, Dunkerque, France.,Department of Dermatology, University Hospital of Lille, Lille, France
| | - N Dupin
- Department of Dermatology, Cochin Hospital, AP-HP, AP-HP, Centre-Université de Paris, Paris, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor University Hospital, AP-HP, Créteil, France.,Univ Paris Est Créteil EpidermE, Créteil, France
| | -
- French Bullous Diseases Study Group Paris, Paris, France
| |
Collapse
|
12
|
Savina A, Jaffredo T, Saldmann F, Faulkes CG, Moguelet P, Leroy C, Marmol DD, Codogno P, Foucher L, Zalc A, Viltard M, Friedlander G, Aractingi S, Fontaine RH. Single-cell transcriptomics reveals age-resistant maintenance of cell identities, stem cell compartments and differentiation trajectories in long-lived naked mole-rats skin. Aging (Albany NY) 2022; 14:3728-3756. [PMID: 35507806 PMCID: PMC9134947 DOI: 10.18632/aging.204054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 04/25/2022] [Indexed: 11/25/2022]
Abstract
Naked mole-rats (NMR) are subterranean rodents characterized by an unusual longevity coupled with an unexplained resistance to aging. In the present study, we performed extensive in situ analysis and single-cell RNA-sequencing comparing young and older animals. At variance with other species, NMR exhibited a striking stability of skin compartments and cell types, which remained stable over time without aging-associated changes. Remarkably, the number of stem cells was constant throughout aging. We found three classical cellular states defining a unique keratinocyte differentiation trajectory that were not altered after pseudo-temporal reconstruction. Epidermal gene expression did not change with aging either. Langerhans cell clusters were conserved, and only a higher basal stem cell expression of Igfbp3 was found in aged animals. In accordance, NMR skin healing closure was similar in young and older animals. Altogether, these results indicate that NMR skin is characterized by peculiar genetic and cellular features, different from those previously demonstrated for mice and humans. The remarkable stability of the aging NMR skin transcriptome likely reflects unaltered homeostasis and resilience.
Collapse
Affiliation(s)
| | - Thierry Jaffredo
- Institut de Biologie Paris Seine (IBPS), Laboratoire de Biologie du Développement, Sorbonne Université, CNRS, INSERM, Paris, France
| | | | - Chris G Faulkes
- Queen Mary University of London, School of Biological and Chemical Sciences, London, United Kingdom
| | - Philippe Moguelet
- Service d'Anatomie et Cytologie Pathologiques, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Christine Leroy
- Université Paris Cité, CNRS, INSERM, Institut Necker-Enfants Malades, Paris, France
| | | | - Patrice Codogno
- Université Paris Cité, CNRS, INSERM, Institut Necker-Enfants Malades, Paris, France
| | - Lucy Foucher
- Ecole Nationale Vétérinaire d'Alfort, Centre de Recherche Biomédicale, Maisons-Alfort, France
| | - Antoine Zalc
- Université Paris Cité, CNRS, INSERM, Institut Cochin, Paris, France
| | - Mélanie Viltard
- Fondation pour la Recherche en Physiologie, Brussels, Belgium
| | - Gérard Friedlander
- Université Paris Cité, CNRS, INSERM, Institut Necker-Enfants Malades, Paris, France
| | - Selim Aractingi
- Université Paris Cité, CNRS, INSERM, Institut Cochin, Paris, France.,Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, France
| | | |
Collapse
|
13
|
London J, Régent A, Dion J, Jilet L, Jachiet M, Lidove O, Cohen-Aubart F, Aractingi S, Guégan S, Pennaforte JL, Abdoul H, Puéchal X, Terrier B. Efficacy and safety of ustekinumab in Behçet disease: Results from the prospective phase 2 STELABEC trial. J Am Acad Dermatol 2021; 87:681-684. [PMID: 34864108 DOI: 10.1016/j.jaad.2021.11.045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2021] [Revised: 10/26/2021] [Accepted: 11/12/2021] [Indexed: 11/17/2022]
Affiliation(s)
- Jonathan London
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, France
| | - Alexis Régent
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, France
| | - Jérémie Dion
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, France
| | - Léa Jilet
- Unité de Recherche Clinique Centre d'Investigation Clinique, Paris Descartes Necker/Cochin, Hôpital Tarnier, France
| | - Marie Jachiet
- Department of Dermatology, Hôpital-Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Olivier Lidove
- Department of Internal Medicine, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France
| | - Fleur Cohen-Aubart
- Sorbonne Université, Service de Médecine Interne 2, Centre de Référence National Lupus Systémique et Syndromes des anti-phospholipides et Autres Maladies Auto-immunes et Systémiques Rares, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, France
| | - Selim Aractingi
- Université de Paris, France; Department of Dermatology, Hôpital Cochin, AP-HP, Paris, France
| | - Sarah Guégan
- Université de Paris, France; Department of Dermatology, Hôpital Cochin, AP-HP, Paris, France
| | - Jean-Loup Pennaforte
- Department of Internal Medicine, Centre Hospitalier Universitaire de Reims, Hôpital Robert Debré, Reims, France
| | - Hendy Abdoul
- Unité de Recherche Clinique Centre d'Investigation Clinique, Paris Descartes Necker/Cochin, Hôpital Tarnier, France
| | - Xavier Puéchal
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, France.
| |
Collapse
|
14
|
Maisonobe L, Korganow A, Deroux A, Dupin N, Aractingi S, Emmi G, Vandergheynst F, Fabre M, Kluger N, Roux M, Abisror N, Cassone G, Cid M, Foucher A, Gobert D, Gombeir Y, Hernandez J, Le Gouellec N, Jachiet M, Terrier B. Utilisation des biothérapies au cours des vascularites urticariennes. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
15
|
Berro S, Calas A, Sohier P, Darbord D, Aractingi S, Dupin N. Syndrome de Sweet secondaire à une infection sévère à SARS-CoV-2. Annales de Dermatologie et de Vénéréologie - FMC 2021. [PMCID: PMC8603742 DOI: 10.1016/j.fander.2021.09.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Introduction De nombreuses manifestations cutanées associées au COVID-19 ont été décrites parmi lesquelles les engelures et les exanthèmes sont les plus fréquentes. Nous rapportons ici le cas d’un syndrome de Sweet survenant 3 semaines après le début d’infection sévère à SARS-CoV-2. Matériel et méthodes Une femme de 51 ans était hospitalisée en réanimation pour une pneumopathie sévère à SARS-CoV-2 compliquée d’embolie pulmonaire. La PCR SARS-CoV-2 nasopharyngée était positive. Une anticoagulation curative, une antibiothérapie par ceftriaxone et rovamycine ainsi que de la dexaméthasone étaient introduits. Trois semaines plus tard, des papulonodules érythémato-violacés apparaissaient sur les membres supérieurs, le tronc et les cuisses. Elle n’avait pas de fièvre ni d’atteinte muqueuse. La CRP était à 186 mg/L sans hyperleucocytose. La PCR SARS-CoV-2 sanguine était négative mais la sérologie positive avec un index d’IgG à 7,96. La biopsie cutanée montrait un infiltrat dermique de polynucléaires neutrophiles, associé à un œdème du derme papillaire, sans vascularite leucocytoclasique confirmant le diagnostic de syndrome de Sweet. Il n’existait pas d’argument clinicobiologique pour une hémopathie ni pour une maladie inflammatoire du tube digestif. Le TEP scanner était sans particularité. On ne retrouvait pas de médicament imputable. Une corticothérapie par voie orale était introduite à 0,5 mg/kg/jour, avec une réponse spectaculaire, sans effet rebond à l’arrêt. Discussion Une équipe turque (Taksin et al.) a décrit le premier cas de syndrome de Sweet lié au COVID-19. Les lésions cutanées étaient concomitantes aux symptômes respiratoires typiques. Nous rapportons ici le deuxième cas d’un syndrome de Sweet lié au COVID-19 survenant 22 jours après l’apparition des symptômes respiratoires. Chez notre patiente, il n’y avait pas d’argument pour une néoplasie, ni pour une atteinte inflammatoire digestive, ni pour une cause médicamenteuse. Le diagnostic de syndrome de Sweet post-infectieux lié au COVID-19 était ainsi proposé. L’infiltration du derme par des polynucléaires neutrophiles a été rapportée au cours de certains manifestations comme les éruptions maculopapuleuses purpuriques et les éruptions d’érythème polymorphe associées au COVID-19. Des séries d’autopsies de poumons de patients décédés en réanimation ont montré une infiltration neutrophilique assez importante. La sévérité de l’infection pourrait être corrélée à l’intensité de la réponse neutrophilique associée. Ainsi le syndrome de Sweet, même si très rarement décrit jusqu’à présent, pourrait être considéré comme un marqueur de sévérité de l’infection, à l’inverse des lésions d’engelures décrites comme étant un facteur de bon pronostic.
Collapse
|
16
|
Annabi E, Dupin N, Garel B, Franck N, Aractingi S, Sohier P, Guegan S, Oulès B. Réactions cutanées rares aux vaccins contre la COVID-19 : série de cas monocentrique et revue de la littérature. Annales de Dermatologie et de Vénéréologie - FMC 2021. [PMCID: PMC8603741 DOI: 10.1016/j.fander.2021.09.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Introduction Les données d’efficacité et de sécurité des vaccins contre la COVID-19 sont rassurantes. Cependant, des effets secondaires cutanés sont souvent rapportés, en particulier des réactions locales au site d’injection. Des effets indésirables cutanés plus rares peuvent également se produire, ce qui peut remettre en question la poursuite de la vaccination. L’objectif de cette étude était de décrire les caractéristiques cliniques et histologiques des effets secondaires cutanés aux vaccins contre la COVID-19 dans un centre parisien (hôpital Cochin, AP–HP, Paris), en excluant les réactions locales au site d’injection, ainsi que les éventuelles récidives après la deuxième dose. Matériel et méthodes Huit patients, âgés de 44 à 80 ans, sans antécédent connu d’infection à SARS-CoV-2 ont été inclus. Des réactions cutanées ont été observées entre 3 et 12 jours après la première dose chez 5, 1 et 2 patients qui ont respectivement reçu le vaccin Pfizer, Moderna et Oxford–AstraZeneca contre la COVID-19. Nous avons observé 2 éruptions morbilliformes, un érythème cutané diffus, une pustulose exanthématique aiguë généralisée, un érythème pigmenté fixe, une plaque œdématiée localisée, des engelures et un livedo racemosa. L’analyse histologique était non spécifique le plus souvent, montrant une spongiose et une dermite de l’interface compatibles avec une réaction médicamenteuse, et dans un cas des caractéristiques compatibles avec des engelures. Les symptômes ont disparu entre 8 et 30 jours, sous dermocorticoïdes chez 50 % des patients ou sans traitement spécifique chez les autres. Deux patients ont récidivé leurs symptômes après la deuxième dose, sans caractère de gravité. Une revue de la littérature a été réalisée et montre des cas similaires de récidive après la deuxième dose de vaccin. Discussion Les réactions cutanées secondaires au vaccin contre la COVID-19 sont polymorphes, mais ressemblent à celles décrites après l’infection à SARS-CoV-2, suggérant une réaction immuno-médiée commune contre la protéine Spike. Les praticiens doivent être sensibilisés à ces manifestations cutanées qui ne contre indiquent pas, le plus souvent, la poursuite de la vaccination.
Collapse
|
17
|
Yatim N, Boussier J, Tetu P, Smith N, Bruel T, Corneau A, Da Meda L, Allayous C, Grzelak L, Staropoli I, Hadjadj J, Le Goff J, Kramkimel N, Aractingi S, Blanc C, Rieux-Laucat F, Schwartz O, Terrier B, Duffy D, Lebbe C. Impact des inhibiteurs de checkpoints immunitaires au cours de la COVID-19 chez les patients atteints de mélanome. Rev Med Interne 2021. [PMCID: PMC8610730 DOI: 10.1016/j.revmed.2021.10.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
18
|
Kolanska K, Sbeih M, Canlorbe G, Mekinian A, Varinot J, Capmas P, Koskas M, Aractingi S, Daraï E, Chabbert-Buffet N. Ulipristal Acetate Modifies miRNA Expression in Both Superficial and Basal Layers of the Human Endometrium. J Clin Med 2021; 10:jcm10194442. [PMID: 34640460 PMCID: PMC8509688 DOI: 10.3390/jcm10194442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2021] [Revised: 09/23/2021] [Accepted: 09/24/2021] [Indexed: 12/05/2022] Open
Abstract
(1) Background: Ulipristal acetate (UPA) is a selective progesterone receptor modulator (SPRM) widely used for emergency contraception and mid- to long-term leiomyoma treatment. The aim of this study was to identify modifications of miRNA expression in superficial and basal layers of the human endometrium at the end of the UPA treatment for at least 3 months. (2) Methods: Microarray miRNA analysis of formalin-fixed, paraffin-embedded hysterectomy tissue samples was conducted, followed by an Ingenuity Pathway Analysis. Samples were divided into three groups: women having had 3 months of UPA treatment (n = 7); and two control groups of UPA-naïve women in the proliferative (n = 8) or secretory (n = 6) phase. (3) Results: The UPA modified the expression of 59 miRNAs involved in the processes of cell cycle, carcinogenesis, and inflammation. Their expression profiles were different in the basal and superficial layers. Most of the processes influenced by the UPA in the basal layer were connected to the cell cycle and immune regulation. (4) Conclusion: Specific changes were observed in both layers of the endometrium in the UPA group. However, the miRNA expression in the basal layer was not consistent with that in the superficial layer. Other large studies analysing the long-term impact of SPRM on endometrial miRNA expression are necessary.
Collapse
Affiliation(s)
- Kamila Kolanska
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 rue Chaligny, CEDEX 12, 75571 Paris, France; (M.S.); (G.C.); (M.K.); (S.A.); (E.D.); (N.C.-B.)
- Service de Gynécologie Sestertius et Médecine de la Reproduction, AP-HP Sorbonne Université Site Tenon, 4 rue de la Chine, 75020 Paris, France
- Correspondence:
| | - Maria Sbeih
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 rue Chaligny, CEDEX 12, 75571 Paris, France; (M.S.); (G.C.); (M.K.); (S.A.); (E.D.); (N.C.-B.)
| | - Geoffroy Canlorbe
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 rue Chaligny, CEDEX 12, 75571 Paris, France; (M.S.); (G.C.); (M.K.); (S.A.); (E.D.); (N.C.-B.)
- Department of Gynecological and Breast Surgery and Oncology, Pitié-Salpêtrière University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), 75013 Paris, France
| | - Arsène Mekinian
- Service de Médecine Interne, AP-HP Sorbonne Université Site St Antoine, 184 rue du Faubourg Saint Antoine, 75012 Paris, France;
| | - Justine Varinot
- Service d’Anatomopathologie, AP HP Sorbonne Université Site Tenon, 4 rue de la Chine, 75020 Paris, France;
| | - Perrine Capmas
- Department of Gynecology and Obstetrics, University Paris Saclay, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France;
- Inserm, Centre of Research in Epidemiology and Population Health (CESP), U1018, 94276 Le Kremlin-Bicêtre, France
| | - Martin Koskas
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 rue Chaligny, CEDEX 12, 75571 Paris, France; (M.S.); (G.C.); (M.K.); (S.A.); (E.D.); (N.C.-B.)
- Department of Obstetrics and Gynecology, AP-HP Bichat University Hospital, 75018 Paris, France
- Institut de Recherche en Santé de la Femme, Equipe d’accueil 7285, Universite de Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-le-Bretonneux, France
| | - Selim Aractingi
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 rue Chaligny, CEDEX 12, 75571 Paris, France; (M.S.); (G.C.); (M.K.); (S.A.); (E.D.); (N.C.-B.)
| | - Emile Daraï
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 rue Chaligny, CEDEX 12, 75571 Paris, France; (M.S.); (G.C.); (M.K.); (S.A.); (E.D.); (N.C.-B.)
- Service de Gynécologie Sestertius et Médecine de la Reproduction, AP-HP Sorbonne Université Site Tenon, 4 rue de la Chine, 75020 Paris, France
| | - Nathalie Chabbert-Buffet
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 rue Chaligny, CEDEX 12, 75571 Paris, France; (M.S.); (G.C.); (M.K.); (S.A.); (E.D.); (N.C.-B.)
- Service de Gynécologie Sestertius et Médecine de la Reproduction, AP-HP Sorbonne Université Site Tenon, 4 rue de la Chine, 75020 Paris, France
| |
Collapse
|
19
|
Annabi E, Dupin N, Sohier P, Garel B, Franck N, Aractingi S, Guégan S, Oulès B. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature. J Eur Acad Dermatol Venereol 2021; 35:e847-e850. [PMID: 34363637 PMCID: PMC8447383 DOI: 10.1111/jdv.17578] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Accepted: 07/30/2021] [Indexed: 01/26/2023]
Affiliation(s)
- E Annabi
- Department of Dermatology, Hôpital Cochin, AP-HP, AP-HP.Centre-Université de Paris, Paris, France
| | - N Dupin
- Department of Dermatology, Hôpital Cochin, AP-HP, AP-HP.Centre-Université de Paris, Paris, France.,Faculté de Médecine Paris Centre Santé, University of Paris, Paris, France.,Cutaneous Biology Lab, Institut Cochin, INSERM, Paris, France
| | - P Sohier
- Faculté de Médecine Paris Centre Santé, University of Paris, Paris, France.,Cutaneous Biology Lab, Institut Cochin, INSERM, Paris, France.,Department of Pathology, Hôpital Cochin, AP-HP, AP-HP.Centre-Université de Paris, Paris, France
| | - B Garel
- Department of Dermatology, Hôpital Cochin, AP-HP, AP-HP.Centre-Université de Paris, Paris, France
| | - N Franck
- Department of Dermatology, Hôpital Cochin, AP-HP, AP-HP.Centre-Université de Paris, Paris, France
| | - S Aractingi
- Department of Dermatology, Hôpital Cochin, AP-HP, AP-HP.Centre-Université de Paris, Paris, France.,Faculté de Médecine Paris Centre Santé, University of Paris, Paris, France.,Cutaneous Biology Lab, Institut Cochin, INSERM, Paris, France
| | - S Guégan
- Department of Dermatology, Hôpital Cochin, AP-HP, AP-HP.Centre-Université de Paris, Paris, France.,Faculté de Médecine Paris Centre Santé, University of Paris, Paris, France.,Cutaneous Biology Lab, Institut Cochin, INSERM, Paris, France
| | - B Oulès
- Department of Dermatology, Hôpital Cochin, AP-HP, AP-HP.Centre-Université de Paris, Paris, France.,Faculté de Médecine Paris Centre Santé, University of Paris, Paris, France.,Cutaneous Biology Lab, Institut Cochin, INSERM, Paris, France
| |
Collapse
|
20
|
Kolanska K, Bendifallah S, Canlorbe G, Mekinian A, Touboul C, Aractingi S, Chabbert-Buffet N, Daraï E. Role of miRNAs in Normal Endometrium and in Endometrial Disorders: Comprehensive Review. J Clin Med 2021; 10:jcm10163457. [PMID: 34441754 PMCID: PMC8396961 DOI: 10.3390/jcm10163457] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 07/15/2021] [Accepted: 07/29/2021] [Indexed: 12/12/2022] Open
Abstract
The molecular responses to hormonal stimuli in the endometrium are modulated at the transcriptional and post-transcriptional stages. Any imbalance in cellular and molecular endometrial homeostasis may lead to gynecological disorders. MicroRNAs (miRNAs) are involved in a wide variety of physiological mechanisms and their expression patterns in the endometrium are currently attracting a lot of interest. miRNA regulation could be hormone dependent. Conversely, miRNAs could regulate the action of sexual hormones. Modifications to miRNA expression in pathological situations could either be a cause or a result of the existing pathology. The complexity of miRNA actions and the diversity of signaling pathways controlled by numerous miRNAs require rigorous analysis and findings need to be interpreted with caution. Alteration of miRNA expression in women with endometriosis has been reported. Thus, a potential diagnostic test supported by a specific miRNA signature could contribute to early diagnosis and a change in the therapeutic paradigm. Similarly, specific miRNA profile signatures are expected for RIF and endometrial cancer, with direct implications for associated therapies for RIF and adjuvant therapies for endometrial cancer. Advances in targeted therapies based on the regulation of miRNA expression are under evaluation.
Collapse
Affiliation(s)
- Kamila Kolanska
- Service de Gynécologie Obstétrique et Médecine de la Reproduction, Hôpital Tenon, AP-HP, Sorbonne Université, 4 Rue de la Chine, 75020 Paris, France; (S.B.); (C.T.); (N.C.-B.); (E.D.)
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 Rue Chaligny, CEDEX 12, 75571 Paris, France; (G.C.); (S.A.)
- Centre Expert En Endométriose (C3E), Groupe de Recherche Clinique en Endométriose (GRC6), Sorbonne Université, 4 Rue de la Chine, 75020 Paris, France
- Correspondence:
| | - Sofiane Bendifallah
- Service de Gynécologie Obstétrique et Médecine de la Reproduction, Hôpital Tenon, AP-HP, Sorbonne Université, 4 Rue de la Chine, 75020 Paris, France; (S.B.); (C.T.); (N.C.-B.); (E.D.)
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 Rue Chaligny, CEDEX 12, 75571 Paris, France; (G.C.); (S.A.)
- Centre Expert En Endométriose (C3E), Groupe de Recherche Clinique en Endométriose (GRC6), Sorbonne Université, 4 Rue de la Chine, 75020 Paris, France
| | - Geoffroy Canlorbe
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 Rue Chaligny, CEDEX 12, 75571 Paris, France; (G.C.); (S.A.)
- Service de Chirurgie et Cancérologie Gynécologique et Mammaire, Hôpitaux Universitaires Pitié-Salpêtrière, Charles-Foix, Sorbonne Université, 47/83, Boulevard de l’Hôpital, 75013 Paris, France
| | - Arsène Mekinian
- Service de Médecine Interne, Hôpital Saint Antoine, AP-HP, 184 Rue du Faubourg Saint Antoine, Sorbonne Université, 75012 Paris, France;
| | - Cyril Touboul
- Service de Gynécologie Obstétrique et Médecine de la Reproduction, Hôpital Tenon, AP-HP, Sorbonne Université, 4 Rue de la Chine, 75020 Paris, France; (S.B.); (C.T.); (N.C.-B.); (E.D.)
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 Rue Chaligny, CEDEX 12, 75571 Paris, France; (G.C.); (S.A.)
- Centre Expert En Endométriose (C3E), Groupe de Recherche Clinique en Endométriose (GRC6), Sorbonne Université, 4 Rue de la Chine, 75020 Paris, France
| | - Selim Aractingi
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 Rue Chaligny, CEDEX 12, 75571 Paris, France; (G.C.); (S.A.)
- Faculté de Médecine Paris 5 Descartes, 12 Rue de l’Ecole de Médecine, 75006 Paris, France
| | - Nathalie Chabbert-Buffet
- Service de Gynécologie Obstétrique et Médecine de la Reproduction, Hôpital Tenon, AP-HP, Sorbonne Université, 4 Rue de la Chine, 75020 Paris, France; (S.B.); (C.T.); (N.C.-B.); (E.D.)
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 Rue Chaligny, CEDEX 12, 75571 Paris, France; (G.C.); (S.A.)
- Centre Expert En Endométriose (C3E), Groupe de Recherche Clinique en Endométriose (GRC6), Sorbonne Université, 4 Rue de la Chine, 75020 Paris, France
| | - Emile Daraï
- Service de Gynécologie Obstétrique et Médecine de la Reproduction, Hôpital Tenon, AP-HP, Sorbonne Université, 4 Rue de la Chine, 75020 Paris, France; (S.B.); (C.T.); (N.C.-B.); (E.D.)
- INSERM UMRS 938, Sorbonne Université, Site Saint-Antoine, 27 Rue Chaligny, CEDEX 12, 75571 Paris, France; (G.C.); (S.A.)
- Centre Expert En Endométriose (C3E), Groupe de Recherche Clinique en Endométriose (GRC6), Sorbonne Université, 4 Rue de la Chine, 75020 Paris, France
| |
Collapse
|
21
|
Yatim N, Boussier J, Tetu P, Smith N, Bruel T, Charbit B, Barnabei L, Corneau A, Da Meda L, Allayous C, Baroudjian B, Jebali M, Herms F, Grzelak L, Staropoli I, Calmettes V, Hadjadj J, Peyrony O, Cassius C, LeGoff J, Kramkimel N, Aractingi S, Fontes M, Blanc C, Rieux-Laucat F, Schwartz O, Terrier B, Duffy D, Lebbé C. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. Sci Adv 2021; 7:7/34/eabg4081. [PMID: 34407944 PMCID: PMC8373136 DOI: 10.1126/sciadv.abg4081] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Accepted: 07/06/2021] [Indexed: 05/04/2023]
Abstract
The COVID-19 pandemic has spread worldwide, yet the role of antiviral T cell immunity during infection and the contribution of immune checkpoints remain unclear. By prospectively following a cohort of 292 patients with melanoma, half of which treated with immune checkpoint inhibitors (ICIs), we identified 15 patients with acute or convalescent COVID-19 and investigated their transcriptomic, proteomic, and cellular profiles. We found that ICI treatment was not associated with severe COVID-19 and did not alter the induction of inflammatory and type I interferon responses. In-depth phenotyping demonstrated expansion of CD8 effector memory T cells, enhanced T cell activation, and impaired plasmablast induction in ICI-treated COVID-19 patients. The evaluation of specific adaptive immunity in convalescent patients showed higher spike (S), nucleoprotein (N), and membrane (M) antigen-specific T cell responses and similar induction of spike-specific antibody responses. Our findings provide evidence that ICI during COVID-19 enhanced T cell immunity without exacerbating inflammation.
Collapse
Affiliation(s)
- Nader Yatim
- Translational Immunology Laboratory, Department of Immunology, Institut Pasteur, F-75015 Paris, France.
- Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France
| | - Jeremy Boussier
- Sorbonne Université, AP-HP Hôpital Saint-Antoine, F-75012 Paris, France
| | - Pauline Tetu
- Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France
| | - Nikaïa Smith
- Translational Immunology Laboratory, Department of Immunology, Institut Pasteur, F-75015 Paris, France
| | - Timothée Bruel
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
| | - Bruno Charbit
- Institut Pasteur, Cytometry and Biomarkers UTechS, CRT, F-75015 Paris, France
| | - Laura Barnabei
- Université de Paris, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Imagine Institute, INSERM UMR 1163, F-75015 Paris, France
| | - Aurélien Corneau
- Sorbonne Université, Faculté de Médecine, UMS037, PASS, Plateforme de Cytométrie de la Pitié-Salpêtrière CyPS, F-75013 Paris, France
| | - Laetitia Da Meda
- Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France
| | - Clara Allayous
- Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France
| | - Barouyr Baroudjian
- Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France
| | - Majdi Jebali
- Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France
| | - Florian Herms
- Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France
| | - Ludivine Grzelak
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
| | - Isabelle Staropoli
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
| | - Vincent Calmettes
- Université de Paris, APHP Hopital Cochin, Department of Dermatology, Paris, France
| | - Jerome Hadjadj
- Université de Paris, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Imagine Institute, INSERM UMR 1163, F-75015 Paris, France
- Université de Paris, APHP Hopital Cochin, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), F-75014 Paris, France
| | - Olivier Peyrony
- APHP Hôpital Saint-Louis, Emergency Department, Paris, France
| | - Charles Cassius
- Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France
| | - Jerome LeGoff
- Université de Paris, INSERM, Equipe INSIGHT, U976, Virology, AP-HP, Hôpital Saint Louis, F-75010 Paris, France
| | - Nora Kramkimel
- Université de Paris, APHP Hopital Cochin, Department of Dermatology, Paris, France
| | - Selim Aractingi
- Université de Paris, APHP Hopital Cochin, Department of Dermatology, Paris, France
| | | | - Catherine Blanc
- Sorbonne Université, Faculté de Médecine, UMS037, PASS, Plateforme de Cytométrie de la Pitié-Salpêtrière CyPS, F-75013 Paris, France
| | - Frederic Rieux-Laucat
- Université de Paris, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Imagine Institute, INSERM UMR 1163, F-75015 Paris, France
| | - Olivier Schwartz
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Creteil, France
| | - Benjamin Terrier
- Université de Paris, APHP Hopital Cochin, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), F-75014 Paris, France
| | - Darragh Duffy
- Translational Immunology Laboratory, Department of Immunology, Institut Pasteur, F-75015 Paris, France
- Institut Pasteur, Cytometry and Biomarkers UTechS, CRT, F-75015 Paris, France
| | - Celeste Lebbé
- Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France.
| |
Collapse
|
22
|
Rodrigues-Braz D, Zhao M, Yesilirmak N, Aractingi S, Behar-Cohen F, Bourges JL. Cutaneous and ocular rosacea: Common and specific physiopathogenic mechanisms and study models. Mol Vis 2021; 27:323-353. [PMID: 34035646 PMCID: PMC8131178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Accepted: 05/11/2021] [Indexed: 11/21/2022] Open
Abstract
Rosacea is a chronic inflammatory disease that affects the face skin. It is clinically classified into the following four subgroups depending on its location and severity: erythematotelangiectatic, papulopustular, phymatous, and ocular. Rosacea is a multifactorial disease triggered by favoring factors, the pathogenesis of which remains imperfectly understood. Recognized mechanisms include the innate immune system, with the implication of Toll-like receptors (TLRs) and cathelicidins; neurovascular deregulation involving vascular endothelial growth factor (VEGF), transient receptor potential (TRP) ion channels, and neuropeptides; and dysfunction of skin sebaceous glands and ocular meibomian glands. Microorganisms, genetic predisposition, corticosteroid treatment, and ultraviolet B (UVB) radiation are favoring factors. In this paper, we review the common and specific molecular mechanisms involved in the pathogenesis of cutaneous and ocular rosacea and discuss laboratory and clinical studies, as well as experimental models.
Collapse
Affiliation(s)
- Daniela Rodrigues-Braz
- Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, Inserm, UMRS1138, Team 17, Physiopathology of ocular diseases: therapeutic innovations, Paris, France
| | - Min Zhao
- Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, Inserm, UMRS1138, Team 17, Physiopathology of ocular diseases: therapeutic innovations, Paris, France
| | - Nilufer Yesilirmak
- Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, Inserm, UMRS1138, Team 17, Physiopathology of ocular diseases: therapeutic innovations, Paris, France
- Department of Ophthalmology, Ankara Yildirim Beyazit University, Ankara, Turkey
- Ophtalmopole, Assistance Publique -Hôpitaux de Paris (AP-HP), Cochin Hospital, Paris, France
| | - Selim Aractingi
- Department of Dermatology, AP-HP, Cochin Hospital, Paris, France
| | - Francine Behar-Cohen
- Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, Inserm, UMRS1138, Team 17, Physiopathology of ocular diseases: therapeutic innovations, Paris, France
- Ophtalmopole, Assistance Publique -Hôpitaux de Paris (AP-HP), Cochin Hospital, Paris, France
| | - Jean-Louis Bourges
- Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, Inserm, UMRS1138, Team 17, Physiopathology of ocular diseases: therapeutic innovations, Paris, France
- Ophtalmopole, Assistance Publique -Hôpitaux de Paris (AP-HP), Cochin Hospital, Paris, France
| |
Collapse
|
23
|
Sohier P, Matar S, Meritet JF, Laurent-Roussel S, Dupin N, Aractingi S. Histopathologic Features of Chilblainlike Lesions Developing in the Setting of the Coronavirus Disease 2019 (COVID-19) Pandemic. Arch Pathol Lab Med 2021; 145:137-144. [PMID: 33501498 DOI: 10.5858/arpa.2020-0613-sa] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/05/2020] [Indexed: 12/15/2022]
Abstract
CONTEXT.— During the coronavirus disease 2019 pandemic, several studies have described a distinctive cutaneous manifestation with a clinical picture resembling chilblains or chilblain lupus in young patients. OBJECTIVE.— To report the histopathologic description of a series of chilblainlike lesions appearing in the context of the severe acute respiratory syndrome coronavirus 2 epidemic. DESIGN.— The study included 13 patients with cutaneous acral lesions resembling chilblains occurring in the setting of suspected severe acute respiratory syndrome coronavirus 2 infection with available skin biopsy. RESULTS.— Two main histopathologic patterns were observed: a chilblainlike histopathologic pattern (10 of 13 cases; 77%) and a thrombotic vasculopathy pattern (3 of 13 cases; 23%). The chilblainlike histopathologic pattern featured a superficial and deep perivascular infiltrate of lymphocytes of varying intensity. This infiltrate was sometimes peri-eccrine and alterations of eccrine glands were present in most cases. Vacuolar alteration of the basal layer of the epidermis was found in a majority of patients. Lichenoid interface dermatitis was rarely present. The thrombotic vasculopathy pattern featured an absent or mild inflammatory infiltrate, multiple intraluminal fibrin thrombi, and ischemic epidermal necrosis. In both patterns, no true vasculitis was observed. No patient tested positive for severe acute respiratory syndrome coronavirus 2 by polymerase chain reaction, possibly because these lesions may represent late cutaneous manifestations of the disease or are associated with an early effective immune response. CONCLUSIONS.— The relationship of chilblainlike lesions to severe acute respiratory syndrome coronavirus 2 requires further investigations. Histopathologic features mimic chilblains, chilblain lupus, and, less frequently, a thrombotic vasculopathy. Response to viral infection might trigger diverse mechanisms leading to the 2 histopathologic patterns described.
Collapse
Affiliation(s)
- Pierre Sohier
- The Department of Pathology (Sohier, Laurent-Roussel), Assistance Publique-Hôpitaux de Paris, AP-HP Centre-Université de Paris, Paris, France.,Université de Paris, Paris, France (Sohier, Dupin, Aractingi)
| | - Stéphanie Matar
- Department of Dermatology and Venereology (Matar, Dupin, Aractingi), Assistance Publique-Hôpitaux de Paris, AP-HP Centre-Université de Paris, Paris, France
| | - Jean-François Meritet
- Department of the Laboratory of Virology (Meritet), Assistance Publique-Hôpitaux de Paris, AP-HP Centre-Université de Paris, Paris, France
| | - Sara Laurent-Roussel
- The Department of Pathology (Sohier, Laurent-Roussel), Assistance Publique-Hôpitaux de Paris, AP-HP Centre-Université de Paris, Paris, France.,Université de Paris, Paris, France (Sohier, Dupin, Aractingi)
| | - Nicolas Dupin
- Department of Dermatology and Venereology (Matar, Dupin, Aractingi), Assistance Publique-Hôpitaux de Paris, AP-HP Centre-Université de Paris, Paris, France.,Université de Paris, Paris, France (Sohier, Dupin, Aractingi).,Cutaneous Biology Lab, Institut Cochin, INSERM U1016, UMR8104, Paris, France (Dupin, Aractingi)
| | - Selim Aractingi
- Department of Dermatology and Venereology (Matar, Dupin, Aractingi), Assistance Publique-Hôpitaux de Paris, AP-HP Centre-Université de Paris, Paris, France.,Université de Paris, Paris, France (Sohier, Dupin, Aractingi).,Cutaneous Biology Lab, Institut Cochin, INSERM U1016, UMR8104, Paris, France (Dupin, Aractingi)
| |
Collapse
|
24
|
Charvet E, Kramkimel N, Chaplain L, Gantzer A, Kassem O, Longvert C, Blom A, Dupin N, Aractingi S, Hamon M, Zimmermann U, Emile JF, Sohier P, Sidibé T, Saiag P, Funck-Brentano E. Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-programmed-death-receptor-1 monoclonal antibodies. Br J Dermatol 2020; 184:746-748. [PMID: 33098566 DOI: 10.1111/bjd.19629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Revised: 10/20/2020] [Accepted: 10/21/2020] [Indexed: 01/10/2023]
Affiliation(s)
- E Charvet
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - N Kramkimel
- Departments of, Department of, Dermatology, Cochin Hospital, AP-HP, Paris, France
| | - L Chaplain
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France.,EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France
| | - A Gantzer
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - O Kassem
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - C Longvert
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France.,EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France
| | - A Blom
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France.,EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France
| | - N Dupin
- Departments of, Department of, Dermatology, Cochin Hospital, AP-HP, Paris, France
| | - S Aractingi
- Departments of, Department of, Dermatology, Cochin Hospital, AP-HP, Paris, France
| | - M Hamon
- Department of, Pathology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - U Zimmermann
- Department of, Pathology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - J-F Emile
- EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France.,Department of, Pathology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - P Sohier
- Department of, Pathology, Cochin Hospital, AP-HP, Paris, France
| | - T Sidibé
- Department of, Pharmacy, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - P Saiag
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France.,EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France
| | - E Funck-Brentano
- Departments of, Department of, General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France.,EA 4340 'Biomarkers and Clinical Trials in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France
| |
Collapse
|
25
|
Bozonnat A, Garel B, Oulès B, Sohier P, Plantier F, Deau-Fischer B, Franck N, Aractingi S, Dupin N. Efficacité de l’ibrutinib dans le traitement d’un xanthogranulome nécrobiotique associé à une lymphocytose B monoclonale. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Dutertre M, Garel B, Tournier A, Oulès B, Franck N, Kramkimel N, Klejtman T, Descamps V, Dupin N, Brunet-Possenti F, Aractingi S, Heure C, Guégan S. Syndrome d’activation macrophagique induit par l’association ipilimumab et nivolumab chez 2 patients atteints de mélanome stade IV. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Charpentier C, Isnard C, Seta V, Quéreux G, Goulvestre C, Lheure C, Kramkimel N, Franck N, Aractingi S, Dupin N. Les pemphigoïdes bulleuses avec sérotype discordant (BP180 +, BP230 −) : identification d’un phénotype clinique singulier ? Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Bettuzzi T, Jachiet M, Sbidian E, Chasset F, Frumholtz L, Cordoliani F, Bouaziz J, Aractingi S, Mouthon L, Guillevin L, Paule R, Terrier B, Dupin N, Régent A. Efficacité et effets indésirables des traitements de la périartérite noueuse cutanée : une étude observationnelle rétrospective. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Calmettes V, Lheure C, Oulès B, Franck N, Chanal J, Garel B, Klejtman T, Guégan S, Brunet-Possenti F, Descamps V, Dupin N, Aractingi S, Kramkimel N. Étude en « vie réelle » de la tolérance du traitement adjuvant par anti-PD1 dans le mélanome stade III ou IV de résection complète. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
Balakirouchenane D, Khoudour N, Guégan S, Kramkimel N, Franck N, Rodier T, Goldwasser F, Dupin N, Aractingi S, Vidal M, Blanchet B. Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2020; 193:113718. [PMID: 33166838 DOI: 10.1016/j.jpba.2020.113718] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Revised: 10/16/2020] [Accepted: 10/17/2020] [Indexed: 12/21/2022]
Abstract
A new liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of dabrafenib (DAB), its main metabolite hydroxy-dabrafenib (OHD) and trametinib (TRA) in human plasma has been developed and validated. After addition of internal standard (dabrafenib-d9), extraction was achieved after protein precipitation with acetonitrile containing 1 % (v/v) formic acid. Chromatographic separation was performed on an Accucore® C18 (2.1 × 50 mm; 2.6 μm) column using a gradient elution of water acidified with 0.1 % (v/v) formic acid (A) and acetonitrile containing 0.1 % (v/v) formic acid (B) at a flow rate of 500 μL/min. The calibration ranged from 10 to 2000 ng/mL for DAB and OHD and from 5 to 50 ng/mL for TRA. This method was validated with satisfactory results including good precision (intra- and inter-assay coefficient of variation from 2.0 %-14.9 %) and good accuracy (inter- and intra-day bias between -1.2 % and 10.9 %), as well as long term stability in unprocessed plasma at -20 °C. This newly proposed method is useful for clinical research purposes as well as therapeutic drug monitoring for patients with a Rapidly Accelerated Fibrosarcoma kinase B (BRAF)-mutated cancer.
Collapse
Affiliation(s)
- David Balakirouchenane
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, University of Paris, PRES Sorbonne Paris Cité, CARPEM, 75006 Paris, France.
| | - Nihel Khoudour
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France
| | - Sarah Guégan
- Department of Dermatology, Cochin Hospital AP-HP, 75014 Paris, France; Cochin Institute, INSERM U1016, University of Paris, 75014 Paris, France
| | - Nora Kramkimel
- Department of Dermatology, Cochin Hospital AP-HP, 75014 Paris, France
| | - Nathalie Franck
- Department of Dermatology, Cochin Hospital AP-HP, 75014 Paris, France
| | - Thomas Rodier
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, University of Paris, PRES Sorbonne Paris Cité, CARPEM, 75006 Paris, France
| | | | - Nicolas Dupin
- Department of Dermatology, Cochin Hospital AP-HP, 75014 Paris, France; Cochin Institute, INSERM U1016, University of Paris, 75014 Paris, France
| | - Selim Aractingi
- Department of Dermatology, Cochin Hospital AP-HP, 75014 Paris, France; Cochin Institute, INSERM U1016, University of Paris, 75014 Paris, France
| | - Michel Vidal
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, University of Paris, PRES Sorbonne Paris Cité, CARPEM, 75006 Paris, France
| | - Benoit Blanchet
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, University of Paris, PRES Sorbonne Paris Cité, CARPEM, 75006 Paris, France
| |
Collapse
|
31
|
Richard MA, Lacour JP, Konstantinou MP, Ruer-Mulard M, Joly P, Aractingi S, Auquier P, Pelvet B, Augustin ML, Mahé E, Chalmers RJG. Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study. J Eur Acad Dermatol Venereol 2020; 35:677-684. [PMID: 32815591 PMCID: PMC7984225 DOI: 10.1111/jdv.16893] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Accepted: 07/09/2020] [Indexed: 11/26/2022]
Abstract
Background The utility of the Simplified Psoriasis Index (SPI), a recently developed multidomain tool for assessing psoriasis, was investigated in a study assessing response to secukinumab. Methods In an open‐label, multicentre study involving 17 French centres, patients with moderate‐to‐severe plaque psoriasis received secukinumab 300 mg subcutaneously once weekly from baseline to W4, then every 4 weeks until W48. Dermatologist‐scored SPI psoriasis severity (proSPI‐s) was compared with Psoriasis Area and Severity Index (PASI). Patient self‐assessed severity (saSPI‐s) and psychosocial impact (SPI‐p) were compared with PASI and Dermatology Life Quality Index (DLQI), respectively. Results We included 120 patients (69.2% male; mean age 45.9 years; mean duration of psoriasis 21.6 years). Mean baseline scores were as follows: proSPI‐s 24.9, saSPI‐s 23.5, PASI 23.1, SPI‐p 8.2 and DLQI 13.6. Severity scores achieved by 16 weeks (proSPI‐s 2.3, saSPI‐s 2.2 and PASI 2.2) were maintained to W52. Reductions in mean psychosocial impact scores were maintained to W52 (SPI‐p and DLQI, respectively, 2.1 and 1.5 at W16; 1.5 and 1.9 at W52). Conclusions Decrease of PASI scores in response to secukinumab was closely correlated with proSPI‐s, supporting the latter's suitability for assessing response to therapy. Although the correlation between PASI and saSPI‐s was slightly weaker, patients were able to complete a valid assessment of their psoriasis independently, and thus potentially remotely. With the added benefit of psychosocial impact assessment (SPI‐p), SPI provides a valid tool enabling patients to assess their own psoriasis, remotely if necessary.
Collapse
Affiliation(s)
- M-A Richard
- CEReSS-EA 3279, Research Centre in Health Services and Quality of Life Aix Marseille University, Marseille, France.,Department of Dermatology, University Hospital Timone Marseille, APHM, Marseille, France
| | - J-P Lacour
- Department of Dermatology, University Hospital of Nice, Archet-2 Hospital, Nice, France
| | - M-P Konstantinou
- Department of Dermatology, Larrey Hospital and Paul Sabatier University, Toulouse, France
| | | | - P Joly
- Department of Dermatology, Rouen University Hospital, University of Rouen Normandie, Rouen, France
| | - S Aractingi
- Department of Dermatology, Cochin-Tarnier Hospital, Paris, France
| | - P Auquier
- CEReSS-EA 3279, Research Centre in Health Services and Quality of Life Aix Marseille University, Marseille, France.,Department of Public Health, University Hospital Timone Marseille, APHM, Marseille, France
| | - B Pelvet
- R&D, Novartis Pharma SAS, Rueil-Malmaison, France
| | - M L Augustin
- R&D, Novartis Pharma SAS, Rueil-Malmaison, France
| | - E Mahé
- Department of Dermatology, Victor Dupouy Hospital, Argenteuil, France
| | - R J G Chalmers
- Centre for Dermatology, University of Manchester, Manchester, UK
| |
Collapse
|
32
|
Matar S, Oulès B, Sohier P, Chosidow O, Beylot-Barry M, Dupin N, Aractingi S. Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. J Eur Acad Dermatol Venereol 2020; 34:e686-e689. [PMID: 32589293 PMCID: PMC7361331 DOI: 10.1111/jdv.16775] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 06/16/2020] [Indexed: 01/08/2023]
Affiliation(s)
- S Matar
- Department of Dermatology, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre Cochin-Hôtel Dieu-Broca, Paris, France
| | - B Oulès
- Department of Dermatology, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre Cochin-Hôtel Dieu-Broca, Paris, France.,Faculté de Médecine Paris Centre Santé, University of Paris, Paris, France.,Cutaneous Biology Lab, INSERM U1016, UMR8104, Institut Cochin, Paris, France
| | - P Sohier
- Faculté de Médecine Paris Centre Santé, University of Paris, Paris, France.,Department of Pathology, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre Cochin-Hôtel Dieu-Broca, Paris, France
| | - O Chosidow
- Department of Dermatology, Hôpital Henri Mondor, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.,Research Group Dynamyc, EA7380, Faculté de Médecine, Université Paris-Est Créteil, Ecole nationale vétérinaire d'Alfort, USC ANSES, Créteil, France
| | - M Beylot-Barry
- Department of Dermatology, CHU Bordeaux, Bordeaux, France.,Bordeaux Research in Translational Oncology, INSERM U1053, Bordeaux, France
| | - N Dupin
- Department of Dermatology, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre Cochin-Hôtel Dieu-Broca, Paris, France.,Faculté de Médecine Paris Centre Santé, University of Paris, Paris, France.,Cutaneous Biology Lab, INSERM U1016, UMR8104, Institut Cochin, Paris, France
| | - S Aractingi
- Department of Dermatology, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre Cochin-Hôtel Dieu-Broca, Paris, France.,Faculté de Médecine Paris Centre Santé, University of Paris, Paris, France.,Cutaneous Biology Lab, INSERM U1016, UMR8104, Institut Cochin, Paris, France
| |
Collapse
|
33
|
Huynh S, Lheure C, Franck N, Goldman-Lévy G, Aractingi S, Dupin N, Kramkimel N, Guégan S. Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study. Melanoma Res 2020; 30:317-320. [PMID: 32053122 DOI: 10.1097/cmr.0000000000000649] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Combined BRAF and MEK inhibition is one of the first-line treatment strategies for patients with advanced BRAF-mutant melanoma. Sarcoid-like reactions (SLRs) have occasionally been described with melanoma systemic treatments such as immunotherapy or the BRAF inhibitor vemurafenib, but very few cases have been reported with dabrafenib and trametinib. Our aim was to better characterize SLR induced by this combination. We conducted a monocentric retrospective observational study among patients treated with dabrafenib and trametinib for BRAF-mutant advanced melanoma from January 2015 to March 2019. Patients presenting with histologically proven SLR were included. We also searched Medline database for all reported cases of SLR induced by targeted therapy. Of 63 patients on dabrafenib/trametinib combination, seven were diagnosed with a SLR. They all had specific cutaneous involvement, and one also displayed mediastinal and salivary glands involvement. None required systemic corticosteroids or dabrafenib/trametinib discontinuation. Three of them (43%) reached melanoma complete remission and are still on targeted therapy; and four patients progressed and died. A literature review yielded 22 additional cases of SLR induced by targeted therapy: the main affected organ was the skin, 11 patients (50%) had systemic involvement, five patients (23%) required systemic corticosteroids to reach partial or complete remission of SLR, 12 (55%) reached partial or complete response of melanoma while six (27%) progressed. BRAF and MEK inhibitors are potential triggers of SLR, although pathological mechanisms remain unclear. The mainstay of treatment is systemic or topical corticotherapy; targeted therapy discontinuation is usually not necessary.
Collapse
Affiliation(s)
- Sandra Huynh
- Department of Dermatology, Hôpital Cochin, AP-HP
| | - Coralie Lheure
- Department of Dermatology, Hôpital Cochin, AP-HP
- Paris Descartes University
| | | | | | - Selim Aractingi
- Department of Dermatology, Hôpital Cochin, AP-HP
- Paris Descartes University
- Cochin Institute, Inserm, Paris, France
| | - Nicolas Dupin
- Department of Dermatology, Hôpital Cochin, AP-HP
- Paris Descartes University
- Cochin Institute, Inserm, Paris, France
| | | | - Sarah Guégan
- Department of Dermatology, Hôpital Cochin, AP-HP
- Paris Descartes University
- Cochin Institute, Inserm, Paris, France
| |
Collapse
|
34
|
Rosenzwajg M, Lorenzon R, Cacoub P, Pitoiset F, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Klatzmann D. THU0051 LOW-DOSE INTERLEUKIN-2 SELECTIVELY EXPAND AND ACTIVATE REGULATORY T CELLS ACROSS 13 AUTOIMMUNE DISEASES. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential for any autoimmune or inflammatory disease (AIID). We performed a disease-finding “basket trial” (TRANSREGNCT01988506) in patients affected by one of 11 different AIID and reported the outcome of the first 46 patients (Rosenzwajg et al, ARD 2019).Objectives:Here we analyzed and discussed results from deep immunophenotyping, of 78 patients, to comprehensively study the effect of ld-IL2 on the immune system of patients affected by various AIIDMethods:We performed a prospective, open label, phase I-IIa study in 78 patients with a mild to moderate form of one of 13 selected AIID. All patients received ld-IL2 (1 million IU/day) for 5 days, followed by fortnightly injections for 6 months. Deep immunophenotyping was performed before and after 5 days of ld-IL2.Results:ld-IL2 significantly expands both memory Tregs as well as naïve Tregs, including recent thymic emigrant Tregs. It also activates Tregs as demonstrated by the significantly increased expression of HLA-DR, CD39, CD73, GITR, CTLA-4. Similar results were observed across the different AIID.Conclusion:ld-IL2 “universally” improves Treg fitness across 13 autoimmune and inflammatory disease.References:[1]Rosenzwajg M#, Lorenzon R#, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, Klatzmann D. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24.Disclosure of Interests:Michelle Rosenzwajg: None declared, Roberta Lorenzon: None declared, Patrice cacoub: None declared, Fabien Pitoiset: None declared, Selim Aractingi: None declared, Beatrice Banneville Speakers bureau: Lilly, Novartis, Laurent Beaugerie: None declared, Francis Berenbaum Grant/research support from: TRB Chemedica (through institution), MSD (through institution), Pfizer (through institution), Consultant of: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Bone Therapeutics, Regulaxis, Peptinov, 4P Pharma, Paid instructor for: Sandoz, Speakers bureau: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Sandoz, Julien Champey: None declared, Olivier Chazouilleres: None declared, Christophe Corpechot: None declared, Bruno Fautrel Grant/research support from: AbbVie, Lilly, MSD, Pfizer, Consultant of: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Lilly, Janssen, Medac MSD France, Nordic Pharma, Novartis, Pfizer, Roche, Sanofi Aventis, SOBI and UCB, Arsene Mekinian: None declared, Elodie Regnier: None declared, david Saadoun: None declared, Joe-Elie Salem: None declared, Jérémie SELLAM: None declared, Philippe Seksik: None declared, David Klatzmann Consultant of: ILTOO Pharma
Collapse
|
35
|
Balakirouchenane D, Guégan S, Csajka C, Jouinot A, Heidelberger V, Puszkiel A, Zehou O, Khoudour N, Courlet P, Kramkimel N, Lheure C, Franck N, Huillard O, Arrondeau J, Vidal M, Goldwasser F, Maubec E, Dupin N, Aractingi S, Guidi M, Blanchet B. Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. Cancers (Basel) 2020; 12:cancers12040931. [PMID: 32283865 PMCID: PMC7226106 DOI: 10.3390/cancers12040931] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 03/30/2020] [Accepted: 04/05/2020] [Indexed: 12/15/2022] Open
Abstract
Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics of DAB, hydroxy-dabrafenib (OHD), and TRA in BRAF-mutated patients and to investigate the exposure–response relationship for toxicity and efficacy in metastatic melanoma (MM) patients. Univariate Fisher and Wilcoxon models including drug systemic exposure (area under the plasma concentration curve, AUC) were used to identify prognostic factors for the onset of dose-limiting toxicities (DLT), and Cox models for overall (OS) and progression-free survival (PFS). Seventy-three BRAF-mutated patients were included in pharmacokinetic (n = 424, NONMEM) and 52 in pharmacokinetic/pharmacodynamic analyses. Age and sex were identified as determinants of DAB and OHD clearances (p < 0.01). MM patients experiencing DLT were overexposed to DAB compared to patients without DLT (AUC: 9624 vs. 7485 ng∙h/mL, respectively, p < 0.01). Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥ 2 and plasma ratio AUCOHD/AUCDAB ≥ 1 were independently associated with shorter OS (HR: 6.58 (1.29–33.56); p = 0.023 and 10.61 (2.34–48.15), p = 0.022, respectively). A number of metastatic sites ≥3 and cerebral metastases were associated with shorter PFS (HR = 3.25 (1.11–9.50); p = 0.032 and HR = 1.23 (1.35–10.39), p = 0.011; respectively). TRA plasma exposure was neither associated with toxicity nor efficacy. Our results suggest that early drug monitoring could be helpful to prevent the onset of DLT in MM patients, especially in fragile patients such as the elderly. Regarding efficacy, the clinical benefit to monitor plasma ratio AUCOHD/AUCDAB deserves more investigation in a larger cohort of MM patients.
Collapse
Affiliation(s)
- David Balakirouchenane
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; (D.B.); (A.P.); (N.K.); (M.V.)
- UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, University of Paris, PRES Sorbonne Paris Cité, CARPEM, 75006 Paris, France
| | - Sarah Guégan
- Department of Dermatology, Cochin Hospital AP-HP, 75014 Paris, France; (S.G.); (N.K.); (C.L.); (N.F.); (N.D.); (S.A.)
- Cochin Institute, INSERM U1016, University of Paris, 75014 Paris, France;
| | - Chantal Csajka
- Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland; (C.C.); (M.G.)
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland
- School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland
| | - Anne Jouinot
- Cochin Institute, INSERM U1016, University of Paris, 75014 Paris, France;
| | - Valentine Heidelberger
- Department of Dermatology, Avicenne Hospital AP-HP, 93000 Bobigny, France; (V.H.); (E.M.)
| | - Alicja Puszkiel
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; (D.B.); (A.P.); (N.K.); (M.V.)
| | - Ouidad Zehou
- Department of Dermatology, Henri Mondor Hospital AP-HP, 94010 Créteil, France;
| | - Nihel Khoudour
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; (D.B.); (A.P.); (N.K.); (M.V.)
| | - Perrine Courlet
- Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland;
| | - Nora Kramkimel
- Department of Dermatology, Cochin Hospital AP-HP, 75014 Paris, France; (S.G.); (N.K.); (C.L.); (N.F.); (N.D.); (S.A.)
| | - Coralie Lheure
- Department of Dermatology, Cochin Hospital AP-HP, 75014 Paris, France; (S.G.); (N.K.); (C.L.); (N.F.); (N.D.); (S.A.)
| | - Nathalie Franck
- Department of Dermatology, Cochin Hospital AP-HP, 75014 Paris, France; (S.G.); (N.K.); (C.L.); (N.F.); (N.D.); (S.A.)
| | - Olivier Huillard
- Department of Medical Oncology, Cochin Hospital AP-HP, 75014 Paris, France; (O.H.); (J.A.); (F.G.)
| | - Jennifer Arrondeau
- Department of Medical Oncology, Cochin Hospital AP-HP, 75014 Paris, France; (O.H.); (J.A.); (F.G.)
| | - Michel Vidal
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; (D.B.); (A.P.); (N.K.); (M.V.)
- UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, University of Paris, PRES Sorbonne Paris Cité, CARPEM, 75006 Paris, France
| | - Francois Goldwasser
- Department of Medical Oncology, Cochin Hospital AP-HP, 75014 Paris, France; (O.H.); (J.A.); (F.G.)
| | - Eve Maubec
- Department of Dermatology, Avicenne Hospital AP-HP, 93000 Bobigny, France; (V.H.); (E.M.)
| | - Nicolas Dupin
- Department of Dermatology, Cochin Hospital AP-HP, 75014 Paris, France; (S.G.); (N.K.); (C.L.); (N.F.); (N.D.); (S.A.)
- Cochin Institute, INSERM U1016, University of Paris, 75014 Paris, France;
| | - Selim Aractingi
- Department of Dermatology, Cochin Hospital AP-HP, 75014 Paris, France; (S.G.); (N.K.); (C.L.); (N.F.); (N.D.); (S.A.)
- Cochin Institute, INSERM U1016, University of Paris, 75014 Paris, France;
| | - Monia Guidi
- Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland; (C.C.); (M.G.)
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland
- Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland;
| | - Benoit Blanchet
- Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France; (D.B.); (A.P.); (N.K.); (M.V.)
- UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, University of Paris, PRES Sorbonne Paris Cité, CARPEM, 75006 Paris, France
- Correspondence: ; Tel.: +331-5841-2313; Fax: +331-5841-2315
| |
Collapse
|
36
|
Eid SA, El Massry M, Hichor M, Haddad M, Grenier J, Dia B, Barakat R, Boutary S, Chanal J, Aractingi S, Wiesel P, Szyndralewiez C, Azar ST, Boitard C, Zaatari G, Eid AA, Massaad C. Targeting the NADPH Oxidase-4 and Liver X Receptor Pathway Preserves Schwann Cell Integrity in Diabetic Mice. Diabetes 2020; 69:448-464. [PMID: 31882567 DOI: 10.2337/db19-0517] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Accepted: 12/15/2019] [Indexed: 11/13/2022]
Abstract
Diabetes triggers peripheral nerve alterations at a structural and functional level, collectively referred to as diabetic peripheral neuropathy (DPN). This work highlights the role of the liver X receptor (LXR) signaling pathway and the cross talk with the reactive oxygen species (ROS)-producing enzyme NADPH oxidase-4 (Nox4) in the pathogenesis of DPN. Using type 1 diabetic (T1DM) mouse models together with cultured Schwann cells (SCs) and skin biopsies from patients with type 2 diabetes (T2DM), we revealed the implication of LXR and Nox4 in the pathophysiology of DPN. T1DM animals exhibit neurophysiological defects and sensorimotor abnormalities paralleled by defective peripheral myelin gene expression. These alterations were concomitant with a significant reduction in LXR expression and increase in Nox4 expression and activity in SCs and peripheral nerves, which were further verified in skin biopsies of patients with T2DM. Moreover, targeted activation of LXR or specific inhibition of Nox4 in vivo and in vitro to attenuate diabetes-induced ROS production in SCs and peripheral nerves reverses functional alteration of the peripheral nerves and restores the homeostatic profiles of MPZ and PMP22. Taken together, our findings are the first to identify novel, key mediators in the pathogenesis of DPN and suggest that targeting LXR/Nox4 axis is a promising therapeutic approach.
Collapse
Affiliation(s)
- Stéphanie A Eid
- Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Faculty of Medicine and Medical Center, Beirut, Lebanon
- INSERM UMR 1124, University Paris Descartes, Faculty of Basic and Biomedical Sciences, Paris, France
| | - Mohamed El Massry
- Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Faculty of Medicine and Medical Center, Beirut, Lebanon
- INSERM UMR 1124, University Paris Descartes, Faculty of Basic and Biomedical Sciences, Paris, France
| | - Mehdi Hichor
- INSERM UMR 1124, University Paris Descartes, Faculty of Basic and Biomedical Sciences, Paris, France
| | - Mary Haddad
- Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Faculty of Medicine and Medical Center, Beirut, Lebanon
| | - Julien Grenier
- INSERM UMR 1124, University Paris Descartes, Faculty of Basic and Biomedical Sciences, Paris, France
| | - Batoul Dia
- Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Faculty of Medicine and Medical Center, Beirut, Lebanon
| | - Rasha Barakat
- Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Faculty of Medicine and Medical Center, Beirut, Lebanon
- INSERM U1016, Cochin Institute, University Paris Descartes, Faculty of Medicine, Sorbonne Paris Cité, Paris, France
| | - Suzan Boutary
- Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Faculty of Medicine and Medical Center, Beirut, Lebanon
| | - Johan Chanal
- INSERM U1016, Cochin Institute, University Paris Descartes, Faculty of Medicine, Sorbonne Paris Cité, Paris, France
| | - Selim Aractingi
- INSERM U1016, Cochin Institute, University Paris Descartes, Faculty of Medicine, Sorbonne Paris Cité, Paris, France
| | | | | | - Sami T Azar
- Department of Internal Medicine, American University of Beirut, Faculty of Medicine and Medical Center, Beirut, Lebanon
- AUB Diabetes, American University of Beirut, Faculty of Medicine and Medical Center, Beirut, Lebanon
| | - Christian Boitard
- INSERM U1016, Cochin Institute, University Paris Descartes, Faculty of Medicine, Sorbonne Paris Cité, Paris, France
| | - Ghazi Zaatari
- Department of Pathology, American University of Beirut, Faculty of Medicine and Medical Center, Beirut, Lebanon
| | - Assaad A Eid
- Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Faculty of Medicine and Medical Center, Beirut, Lebanon
- AUB Diabetes, American University of Beirut, Faculty of Medicine and Medical Center, Beirut, Lebanon
| | - Charbel Massaad
- INSERM UMR 1124, University Paris Descartes, Faculty of Basic and Biomedical Sciences, Paris, France
| |
Collapse
|
37
|
Kouby F, Chanal J, Jafari A, Ermisch C, Farhi D, Aractingi S, Avril MF. [Rieger-Marchac flaps: Complications and patient satisfaction]. Ann Dermatol Venereol 2020; 147:265-270. [PMID: 32057451 DOI: 10.1016/j.annder.2019.01.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Revised: 11/26/2018] [Accepted: 01/23/2019] [Indexed: 11/30/2022]
Abstract
PURPOSE Like all surgical procedures, dorsal nasal flaps may be followed by both early and late complications. The aim of this study was to evaluate the surgical complications and cosmetic outcome of dorsal nasal flaps over a 7-year period in an academic dermatologic surgery unit. PATIENTS AND METHODS Data were collected retrospectively for all patients undergoing dorsal nasal flap between 1 January 2006 and 31 December 2013. Early and late complications were recorded. Patients were contacted by phone to assess long-term outcomes. RESULTS A total of 35 patients were included. Early complications included bleeding (n=2), local infection (n=2) and focal flap necrosis (n=1). Late complications comprised flap thickening (n=7), restriction of the medial canthus (n=2), opening of the labionasal angle (n=1), stitch granuloma (n=1) and telangiectasia on the flap (n=1). Regarding the aesthetic result, seven patients were very satisfied with the flap. Four patients underwent corrective surgery and one patient had laser treatment for telangiectasia on the flap. CONCLUSION Two thirds of patients were satisfied with the aesthetic results and one third had late complications of the flap. Consequently, patients undergoing Rieger-Marchac procedures must be informed of the potential need for further corrective measures following nasal dorsal flap repair.
Collapse
Affiliation(s)
- F Kouby
- Service de dermatologie, université Paris Descartes, hôpital Cochin-Centre Tarnier, Assistance publique-Hôpitaux de Paris, 89, rue d'Assas, 75006 Paris, France
| | - J Chanal
- Service de dermatologie, université Paris Descartes, hôpital Cochin-Centre Tarnier, Assistance publique-Hôpitaux de Paris, 89, rue d'Assas, 75006 Paris, France.
| | - A Jafari
- Service de dermatologie, université Paris Descartes, hôpital Cochin-Centre Tarnier, Assistance publique-Hôpitaux de Paris, 89, rue d'Assas, 75006 Paris, France; Service d'ORL, hôpital Tenon, Assistance publique-Hôpitaux de Paris, Paris, France
| | - C Ermisch
- Service de dermatologie, université Paris Descartes, hôpital Cochin-Centre Tarnier, Assistance publique-Hôpitaux de Paris, 89, rue d'Assas, 75006 Paris, France
| | - D Farhi
- 8, rue Saint-Gilles, Paris, France
| | - S Aractingi
- Service de dermatologie, université Paris Descartes, hôpital Cochin-Centre Tarnier, Assistance publique-Hôpitaux de Paris, 89, rue d'Assas, 75006 Paris, France
| | - M-F Avril
- Service de dermatologie, université Paris Descartes, hôpital Cochin-Centre Tarnier, Assistance publique-Hôpitaux de Paris, 89, rue d'Assas, 75006 Paris, France
| |
Collapse
|
38
|
Galmiche S, Lheure C, Kramkimel N, Franck N, Boitier F, Dupin N, Turc G, Psimaras D, Aractingi S, Guégan S. Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study. J Eur Acad Dermatol Venereol 2019; 33:e440-e443. [PMID: 31219194 DOI: 10.1111/jdv.15756] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2023]
Affiliation(s)
- S Galmiche
- Department of Dermatology, Hôpital Cochin, Paris, France
| | - C Lheure
- Department of Dermatology, Hôpital Cochin, Paris, France
- Université Paris Descartes, Paris, France
| | - N Kramkimel
- Department of Dermatology, Hôpital Cochin, Paris, France
| | - N Franck
- Department of Dermatology, Hôpital Cochin, Paris, France
| | - F Boitier
- Department of Dermatology, Hôpital Cochin, Paris, France
| | - N Dupin
- Department of Dermatology, Hôpital Cochin, Paris, France
- Université Paris Descartes, Paris, France
| | - G Turc
- Departement of Neurology, Centre Hospitalier Sainte Anne, Paris, France
| | - D Psimaras
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France
- OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic Treatments, Hôpitaux Universitaires Pitié-Salpetrière-Charles Foix et Hôpital Percy, Paris, France
| | - S Aractingi
- Department of Dermatology, Hôpital Cochin, Paris, France
- Université Paris Descartes, Paris, France
| | - S Guégan
- Department of Dermatology, Hôpital Cochin, Paris, France
- Université Paris Descartes, Paris, France
| |
Collapse
|
39
|
Charvet E, Kramkimel N, Dupin N, Klejtman T, Isnard C, Chanal J, Aractingi S, Franck N, Lheure C. Étude en « vie réelle » de l’efficacité et de la toxicité de l’association ipilimumab et nivolumab dans le mélanome métastatique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
40
|
Richard MA, Aractingi S, Joly P, Mahé E, Auquier P, Le Guen S, Acquadro C, Boucher F, Chalmers RJG. [French adaptation of a new score for global assessment of psoriasis severity: The Simplified Psoriasis Index (SPI)]. Ann Dermatol Venereol 2019; 146:783-792. [PMID: 31623858 DOI: 10.1016/j.annder.2019.08.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Revised: 03/18/2019] [Accepted: 08/05/2019] [Indexed: 10/25/2022]
Abstract
OBJECTIVE Although several scores exist to assess psoriasis severity, most have marked limitations that rule out their use in routine clinical practice. A new score, the Simplified Psoriasis Index (SPI), has recently been developed and validated in adults in Britain for such use. It has separate components for current severity (SPI-s), psychosocial impact (SPI-p) and past history and interventions (SPI-p), and it is suitable for either professional assessment or patient self-assessment. The aim of this work was to produce a validated translation of SPI into French (as spoken in France). METHODS The index was translated and validated using a strict methodology comprising respectively five and eight phases for the professional (proSPI) and self-administered instruments (saSPI). Translation of the saSPI instrument also involved a cognitive debriefing with five psoriasis patients. RESULTS Linguistic discrepancies and subtle differences of meaning arising during the process were closely examined. The developer of the instrument ensured conceptual accuracy. A panel of health experts guaranteed that medical terms were correctly translated. Five patients with plaque psoriasis (two female and three male of median age 45 years [range: 31-78]) tested the SPI-p version during cognitive interviews and found the questionnaire clear and easy to understand. CONCLUSION Validated French translations of both SPI instruments are now available for use in routine clinical practice. Further investigations are currently underway to validate the psychometric properties of the instrument.
Collapse
Affiliation(s)
- M A Richard
- EA 3279, département de dermatologie, centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix-Marseille université, hôpital de La Timone, Assistance publique-hôpitaux de Marseille, 13385 Marseille, France.
| | - S Aractingi
- Dermatologie, hôpital Cochin-Tarnier, 89, rue d'Assas, 75006 Paris, France
| | - P Joly
- Service de dermatologie, CHU de Charles Nicolle, université de Normandie, 76000 Rouen, France
| | - E Mahé
- Dermatologie, hôpital Victor Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100 Argenteuil, France
| | - P Auquier
- EA 3279, centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix-Marseille université, 13385 Marseille, France
| | - S Le Guen
- R&D, Novartis pharma SAS, 92506 Rueil-Malmaison, France
| | - C Acquadro
- Languages services, Mapi, an ICON plc Company, 69000 Lyon, France
| | - F Boucher
- Languages services, Mapi, an ICON plc Company, 69000 Lyon, France
| | - R J G Chalmers
- Centre for Dermatology, University of Manchester, Manchester, Royaume-Uni
| |
Collapse
|
41
|
Rouillé T, Aractingi S, Kadlub N, Fraitag S, How-Kit A, Moguelet P, Picard A, Fontaine R, Guégan S. 530 Local inhibition of MEK/AKT prevents cellular growth in human congenital melanocytic nevi. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
42
|
Nguyen VT, Farman N, Aractingi S, Jaisser F. Abstract P2021: Cutaneous Wound Healing in Diabetic Mice is Improved by Topical Mineralocorticoid Receptor Blockade. Hypertension 2019. [DOI: 10.1161/hyp.74.suppl_1.p2021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction:
Chronic skin ulcers resulting from impaired wound healing are a serious complication of diabetes. Unresolved inflammation, associated with the dysregulation of both the phenotype and function of macrophages, is involved in the poor healing of diabetic wounds.
Objective:
To investigate the role of the mineralocorticoid receptor in the healing delay and specifically in the impaired angiogenesis and prolonged inflammation of diabetic wounds.
Methods:
6 mm wounds were created on the back skin of female streptozotocin (STZ)-induced or db/db mice. Wounds were treated topically with canrenoate (Canre: 0.5mM) or PBS twice a day, for 5 (STZ mice) or 7 (db/db mice) days. Wound area was measured at indicated time post-wounding. Wounded skin was collected for histology and molecular analysis.
Results:
topical pharmacological inhibition of the MR by Canre can resolve prolonged inflammation to improve delayed skin wound healing in diabetic mouse models. The improvement is demonstrated by increasing of 39% of neo-epidermisation and 62% of epidermal keratinocyte proliferation in db/db wounds treated by Canre. Moreover, Canre could improve the reduced blood vessel density in the wound beds of STZ mice (STZ + PBS: 5.33% ± 0.32 vs STZ + Canre: 8.26% ± 0.64) and of db/db mice (db/db + PBS: 1.32% ± 0.29 vs db/db + Canre: 3.31% ± 0.33). The beneficial effect of Canre is associated with an increased ratio of anti-inflammatory M2 macrophages to pro-inflammatory M1 macrophages in diabetic wounds (ratio of M2 to M1 in db/db + PBS vs db/db + Canre: 0.72 ± 0.15 vs 1.72 ± 0.29, respectively). Furthermore, we show that MR blockade leads to downregulated expression of a MR target, lipocalin 2 (Lcn2), which may facilitate macrophage polarization towards the M2 phenotype and promote impaired angiogenesis in diabetic wounds. Indeed, diabetic Lcn2-deficient mice showed improved wound healing, associated with macrophage M2 polarization and angiogenesis. In addition, recombinant Lcn2 protein prevented IL4-induced macrophages switch from M1 to M2 phenotype.
Conclusion:
topical MR blockade accelerates skin wound healing in diabetic mice via Lcn2 reduction, M2 macrophage polarization, prevention of prolonged inflammation, and induction of angiogenesis.
Collapse
|
43
|
Bettuzzi T, Deroux A, Jachiet M, Farhat MM, Wipff J, Fabre M, Bouillet L, Kramkimel N, Aractingi S, Dupin N, Terrier B. Dramatic but suspensive effect of interleukin-1 inhibitors for persistent urticarial vasculitis: a French multicentre retrospective study. Ann Rheum Dis 2019; 78:1446-1448. [PMID: 31189550 DOI: 10.1136/annrheumdis-2019-215605] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 05/21/2019] [Accepted: 06/06/2019] [Indexed: 11/04/2022]
Affiliation(s)
| | - Alban Deroux
- Department of Internal medicine, Centre Hospitalier Universitaire Grenoble, Michallon Hospital, Grenoble, France
| | - Marie Jachiet
- Department of Dermatology, Hôpital Saint-Louis, Paris, France
| | - Meryem-Maud Farhat
- Department of Internal Medicine, CHRU Lille Pôle Spécialités Médicochirurgicales, Lille, France
| | - Julien Wipff
- Department of Rheumatology, Hopital Cochin, Paris, France
| | - Marc Fabre
- Department of Internal Medicine, Pierre Oudot Hospital of Bourgoin-Jallieu, Bourgoin-Jallieu, France
| | - Laurence Bouillet
- Department of Internal medicine, Centre Hospitalier Universitaire Grenoble, Michallon Hospital, Grenoble, France
| | - Nora Kramkimel
- Department of Dermatology, Hôpital Cochin, Paris, France
| | | | - Nicolas Dupin
- Department of Dermatology, Hôpital Cochin, Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine, Cochin Hospital, Paris, France .,National Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Paris, France
| |
Collapse
|
44
|
Bettuzzi T, Deroux A, Jachiet M, Farhat M, Wipff J, Fabre M, Aractingi S, Dupin N, Terrier B. Traitement des vascularites urticariennes réfractaires par anti-IL-1béta. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
45
|
Rouillé T, Aractingi S, Kadlub N, Fraitag S, How-Kit A, Daunay A, Hivelin M, Moguelet P, Picard A, Fontaine RH, Guégan S. Local Inhibition of MEK/Akt Prevents Cellular Growth in Human Congenital Melanocytic Nevi. J Invest Dermatol 2019; 139:2004-2015.e13. [PMID: 31059696 DOI: 10.1016/j.jid.2019.03.1156] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Revised: 03/20/2019] [Accepted: 03/26/2019] [Indexed: 12/15/2022]
Abstract
The management of large congenital melanocytic nevi (lCMN) is based exclusively on iterative surgical procedures in the absence of validated medical therapy. The aim of our study was to develop an intra-lesional medical treatment for lCMN. Seventeen patients harboring NRAS-mutated lCMN were included. Nevocytes obtained from lCMN displayed an overactivation of mitogen-activated protein kinase and phosphoinositide 3-kinase (Akt) pathways. Mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) and Akt inhibitors reduced the nevosphere diameter in sphere-forming assays, as well as cell viability and proliferation in in vitro assays. Standardized lCMN explants were then cultured ex vivo with the same inhibitors, which induced a decrease in MelanA+ and Sox10+ cells in both epidermis and dermis. Finally, intradermal injections of these inhibitors were administered within standardized lCMN xenografts in Rag2-/- mice. They induced a dramatic decrease in nevocytes in treated xenografts, which persisted 30 days after the end of treatment. Using original nevus explant and xenograft preclinical models, we demonstrated that intradermal MEK/Akt inhibition might serve as neoadjuvant therapy for the treatment of NRAS-mutated congenital melanocytic nevi to avoid iterative surgeries.
Collapse
Affiliation(s)
- Thomas Rouillé
- Saint-Antoine Research Center, INSERM UMRS_938, Paris, France; Sorbonne Université, Paris, France
| | - Selim Aractingi
- Saint-Antoine Research Center, INSERM UMRS_938, Paris, France; Université Paris-Descartes, Paris, France; AP-HP, Hôpital Cochin, Department of Dermatology, Paris, France
| | - Natacha Kadlub
- Université Paris-Descartes, Paris, France; AP-HP, Hôpital Necker-Enfants-Malades, Department of Maxillofacial and Plastic Surgery, Paris, France
| | - Sylvie Fraitag
- AP-HP, Hôpital Necker-Enfants-Malades, Department of Pathology, Paris, France
| | - Alexandre How-Kit
- Laboratory for Functional Genomics, Fondation Jean Dausset-CEPH, Paris, France
| | - Antoine Daunay
- Laboratory for Functional Genomics, Fondation Jean Dausset-CEPH, Paris, France
| | - Mikael Hivelin
- Université Paris-Descartes, Paris, France; AP-HP, Hôpital Européen Georges-Pompidou, Department of Plastic Surgery, Paris, France
| | | | - Arnaud Picard
- Université Paris-Descartes, Paris, France; AP-HP, Hôpital Necker-Enfants-Malades, Department of Maxillofacial and Plastic Surgery, Paris, France
| | - Romain H Fontaine
- Saint-Antoine Research Center, INSERM UMRS_938, Paris, France; Sorbonne Université, Paris, France
| | - Sarah Guégan
- Saint-Antoine Research Center, INSERM UMRS_938, Paris, France; Université Paris-Descartes, Paris, France; AP-HP, Hôpital Cochin, Department of Dermatology, Paris, France.
| |
Collapse
|
46
|
Chanal J, Kramkimel N, Ratour C, Aractingi S, Guégan S, Avril MF. Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age. Dermatology 2019; 235:219-224. [DOI: 10.1159/000492467] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Accepted: 07/26/2018] [Indexed: 11/19/2022] Open
Abstract
Background: Programmed cell death protein-1 (PD-1) inhibitors (pembrolizumab and nivolumab) have been approved for the treatment of advanced melanoma. Over the past decades, patients older than 85 years represent an expanding group of patients in developed countries. In France, 25% of melanomas are diagnosed in patients older than 75 years. Objective: To perform a monocentric retrospective study of patients older than 85 years and treated with pembrolizumab for unresectable or metastatic melanoma in order to evaluate tolerance and potential benefits of this immunotherapy. Methods: Medical records of patients treated with the PD-1 inhibitor pembrolizumab between January 2015 and January 2018 were reviewed. Results: Nine patients (6 women and 3 men) older than 85 years were included in the study. The mean age was 89.6 (85–97) years at inclusion. All patients were PS 0 or 1. The mean number of infusions was 4 (1–12). However, most patients were not able to tolerate the 4-infusion schedule. One patient refused the second infusion for personal reasons. Seven patients had grade 3 or 4 treatment-related adverse events. Conclusion: These results indicate that pembrolizumab treatment in patients older than 85 years may induce responses but is associated with a high risk of toxicity and impaired autonomy.
Collapse
|
47
|
Lheure C, Hoffmann C, Kramkimel N, Plée J, Franck N, Vanhaecke C, Goldman-Lévy G, Bataillon G, Damotte D, Dupin N, Aractingi S, Grange F, Guégan S. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1. Acta Derm Venereol 2019; 99:107-108. [PMID: 30176045 DOI: 10.2340/00015555-3028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Coralie Lheure
- Dermatology Department, Hôpital Cochin AP-HP, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Kolanska K, Varinot J, Canlorbe G, Bergeron C, Mekinian A, Capmas P, Koskas M, Daraï E, Aractingi S, Bendifallah S, Chabbert-Buffet N. Absence of predictable long-term molecular effect of ulipristal acetate (UPA) on the endometrium. Reprod Biomed Online 2018; 38:825-834. [PMID: 30898512 DOI: 10.1016/j.rbmo.2018.12.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Revised: 10/19/2018] [Accepted: 12/11/2018] [Indexed: 10/27/2022]
Abstract
RESEARCH QUESTION What are the effects of ulipristal acetate (UPA) on the expression of endometrial proliferation and maturation markers? DESIGN A total of 45 endometrium-containing blocks of hysterectomy samples from non-menopausal women with a diagnosis of moderate to severe symptoms of uterine fibroids: 14 women operated on at the end of a 3-month course of UPA; four women who had discontinued UPA treatment 1-12 months before surgery; 27 control unexposed samples (14 in the proliferative and 13 in the secretory phase). Immunohistochemical staining of Ki67, vascular endothelial growth factor-receptor 2 (VEGFR2), oestradiol receptor, progesterone receptor, interleukin-15 (IL-15), indoleamin-2,3-dioxygenase (IDO) and C-C motif chemokine ligand-2 (CCL2) markers were analysed in both endometrial compartments and layers. RESULTS Under UPA, oestradiol receptor and progesterone receptor expression is similar to the proliferative phase in both layers, although with a decrease in cell proliferation. IL-15, IDO and CCL2 expressions are similar to the proliferative phase, suggesting a progesterone-antagonist effect of UPA. VEGFR2 staining suggests a trend to a mixed agonist-antagonist effect. No significant difference is observed in the post-UPA proliferative phase group compared with the control group in both layers of the endometrium. CONCLUSION The effect of 3-month UPA treatment is mostly progesterone receptor antagonist-like. After treatment is discontinued, there are no signs of any long-term effects of this molecule on endometrial proliferation and maturation. Therefore, UPA may be administered to women willing to conceive in the short term without consequences for further implantation.
Collapse
Affiliation(s)
- Kamila Kolanska
- Service de gynécologie obstétrique et médecine de la reproduction, Hôpital Tenon, AP-HP, Sorbonne Université, 4 rue de la Chine, Paris 75020, France; INSERM UMRS 938, Faculté de médecine Pierre et Marie Curie, Site Saint-Antoine, 27 rue Chaligny, PARIS cedex 12 75571, France
| | - Justine Varinot
- Service d'anatomopathologie, Hôpital Tenon, AP-HP, Sorbonne Université, 4 rue de la Chine, Paris 75020, France
| | - Geoffroy Canlorbe
- INSERM UMRS 938, Faculté de médecine Pierre et Marie Curie, Site Saint-Antoine, 27 rue Chaligny, PARIS cedex 12 75571, France; Service de chirurgie et cancérologie gynécologique et mammaire, Hôpitaux Universitaires Pitié-Salpêtrière, Charles-Foix, Sorbonne Université, 47/83, boulevard de l'Hôpital, Paris 75013, France
| | | | - Arsène Mekinian
- Service de médecine interne, Hôpital Saint Antoine, AP-HP, 184 rue du Faubourg Saint Antoine, Sorbonne Université, Paris 75012, France
| | - Perrine Capmas
- Service de gynécologie obstétrique, CHU de Bicêtre, AP-HP, 78, rue du Général-Leclerc, Le Kremlin-Bicêtre 94270, France
| | - Martin Koskas
- Service de gynécologie obstétrique, CHU de Bichat, AP-HP, Paris 75018, France
| | - Emile Daraï
- Service de gynécologie obstétrique et médecine de la reproduction, Hôpital Tenon, AP-HP, Sorbonne Université, 4 rue de la Chine, Paris 75020, France; INSERM UMRS 938, Faculté de médecine Pierre et Marie Curie, Site Saint-Antoine, 27 rue Chaligny, PARIS cedex 12 75571, France
| | - Selim Aractingi
- INSERM UMRS 938, Faculté de médecine Pierre et Marie Curie, Site Saint-Antoine, 27 rue Chaligny, PARIS cedex 12 75571, France; Faculté de médecine Paris 5 Descartes, 12 rue de l'Ecole de Médecine, Paris 75006, France
| | - Sofiane Bendifallah
- Service de gynécologie obstétrique et médecine de la reproduction, Hôpital Tenon, AP-HP, Sorbonne Université, 4 rue de la Chine, Paris 75020, France; INSERM UMRS 938, Faculté de médecine Pierre et Marie Curie, Site Saint-Antoine, 27 rue Chaligny, PARIS cedex 12 75571, France
| | - Nathalie Chabbert-Buffet
- Service de gynécologie obstétrique et médecine de la reproduction, Hôpital Tenon, AP-HP, Sorbonne Université, 4 rue de la Chine, Paris 75020, France; INSERM UMRS 938, Faculté de médecine Pierre et Marie Curie, Site Saint-Antoine, 27 rue Chaligny, PARIS cedex 12 75571, France.
| |
Collapse
|
49
|
Kramkimel N, Kurihara F, Seta V, Lheure C, Heidelberger V, Guegan S, Isnard C, Franck N, Avril MF, Aractingi S, Chanal J, Dupin N. Première étude en « vie réelle » comparant le pembrolizumab et le nivolumab dans le traitement du mélanome métastatique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
50
|
Mongereau M, Lheure C, Guegan S, Franck N, Paepegaey AC, Dohan A, Isnard C, Seta V, Chanal J, Dupin N, Aractingi S, Kramkimel N. Hypophysites sous immunothérapie : une complication potentiellement grave à ne pas méconnaître. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|